CN1810970A - CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application - Google Patents
CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application Download PDFInfo
- Publication number
- CN1810970A CN1810970A CNA2005100029570A CN200510002957A CN1810970A CN 1810970 A CN1810970 A CN 1810970A CN A2005100029570 A CNA2005100029570 A CN A2005100029570A CN 200510002957 A CN200510002957 A CN 200510002957A CN 1810970 A CN1810970 A CN 1810970A
- Authority
- CN
- China
- Prior art keywords
- seq
- antigen
- cpg
- hsp
- antigen peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 229960005486 vaccine Drugs 0.000 title claims abstract description 26
- 108091007433 antigens Proteins 0.000 claims abstract description 138
- 239000000427 antigen Substances 0.000 claims abstract description 132
- 102000036639 antigens Human genes 0.000 claims abstract description 132
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 92
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000009385 viral infection Effects 0.000 claims abstract description 6
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 56
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 56
- 230000004927 fusion Effects 0.000 claims description 40
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 34
- 241000711549 Hepacivirus C Species 0.000 claims description 34
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 30
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 25
- 102100034256 Mucin-1 Human genes 0.000 claims description 23
- 238000012986 modification Methods 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 108700042132 Chlamydia trachomatis omp1 Proteins 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 101710132601 Capsid protein Proteins 0.000 claims description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims description 5
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 102000037865 fusion proteins Human genes 0.000 abstract description 13
- 108020001507 fusion proteins Proteins 0.000 abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000035939 shock Effects 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 2
- 208000007190 Chlamydia Infections Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000036281 parasite infection Effects 0.000 abstract 1
- 239000005289 controlled pore glass Substances 0.000 description 236
- 108020004414 DNA Proteins 0.000 description 194
- 210000004027 cell Anatomy 0.000 description 106
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 91
- 241000699666 Mus <mouse, genus> Species 0.000 description 46
- 239000002504 physiological saline solution Substances 0.000 description 26
- 102100038358 Prostate-specific antigen Human genes 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 230000002265 prevention Effects 0.000 description 15
- 239000012636 effector Substances 0.000 description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 9
- 108010035988 Mycobacterium heat-shock protein 65 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000606153 Chlamydia trachomatis Species 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229940038705 chlamydia trachomatis Drugs 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- -1 phosphoramidite triester Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 108010037850 glycylvaline Proteins 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LGYCLOCORAEQSZ-PEFMBERDSA-N Glu-Ile-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O LGYCLOCORAEQSZ-PEFMBERDSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- GCHCDBOIRFPABI-UHFFFAOYSA-N NP(O)O.C1=NN=NN1.C1=NN=NN1 Chemical compound NP(O)O.C1=NN=NN1.C1=NN=NN1 GCHCDBOIRFPABI-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 description 1
- OKEWAFFWMHBGPT-XPUUQOCRSA-N Ala-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 OKEWAFFWMHBGPT-XPUUQOCRSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 1
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
- GFMWTFHOZGLTLC-AVGNSLFASA-N Arg-His-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(O)=O GFMWTFHOZGLTLC-AVGNSLFASA-N 0.000 description 1
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 1
- VRTWYUYCJGNFES-CIUDSAMLSA-N Arg-Ser-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O VRTWYUYCJGNFES-CIUDSAMLSA-N 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- YNDLOUMBVDVALC-ZLUOBGJFSA-N Asn-Ala-Ala Chemical compound C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)N YNDLOUMBVDVALC-ZLUOBGJFSA-N 0.000 description 1
- IYVSIZAXNLOKFQ-BYULHYEWSA-N Asn-Asp-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IYVSIZAXNLOKFQ-BYULHYEWSA-N 0.000 description 1
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 1
- KFAFUJMGHVVYRC-DCAQKATOSA-N Asp-Leu-Met Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O KFAFUJMGHVVYRC-DCAQKATOSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- XMTDCXXLDZKAGI-ACZMJKKPSA-N Cys-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XMTDCXXLDZKAGI-ACZMJKKPSA-N 0.000 description 1
- HRJLVSQKBLZHSR-ZLUOBGJFSA-N Cys-Asn-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O HRJLVSQKBLZHSR-ZLUOBGJFSA-N 0.000 description 1
- AFYGNOJUTMXQIG-FXQIFTODSA-N Cys-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N AFYGNOJUTMXQIG-FXQIFTODSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- CYTSBCIIEHUPDU-ACZMJKKPSA-N Gln-Asp-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O CYTSBCIIEHUPDU-ACZMJKKPSA-N 0.000 description 1
- QKWBEMCLYTYBNI-GVXVVHGQSA-N Gln-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O QKWBEMCLYTYBNI-GVXVVHGQSA-N 0.000 description 1
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 1
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 1
- XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 1
- PMSMKNYRZCKVMC-DRZSPHRISA-N Glu-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)O)N PMSMKNYRZCKVMC-DRZSPHRISA-N 0.000 description 1
- CBWKURKPYSLMJV-SOUVJXGZSA-N Glu-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CBWKURKPYSLMJV-SOUVJXGZSA-N 0.000 description 1
- BXSZPACYCMNKLS-AVGNSLFASA-N Glu-Ser-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BXSZPACYCMNKLS-AVGNSLFASA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- LGQZOQRDEUIZJY-YUMQZZPRSA-N Gly-Cys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CS)NC(=O)CN)C(O)=O LGQZOQRDEUIZJY-YUMQZZPRSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- DUAWRXXTOQOECJ-JSGCOSHPSA-N Gly-Tyr-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O DUAWRXXTOQOECJ-JSGCOSHPSA-N 0.000 description 1
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 1
- QLBXWYXMLHAREM-PYJNHQTQSA-N His-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N QLBXWYXMLHAREM-PYJNHQTQSA-N 0.000 description 1
- MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 1
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 1
- RIMMMMYKGIBOSN-DCAQKATOSA-N Leu-Asn-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O RIMMMMYKGIBOSN-DCAQKATOSA-N 0.000 description 1
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 1
- BPANDPNDMJHFEV-CIUDSAMLSA-N Leu-Asp-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O BPANDPNDMJHFEV-CIUDSAMLSA-N 0.000 description 1
- DXYBNWJZJVSZAE-GUBZILKMSA-N Leu-Gln-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N DXYBNWJZJVSZAE-GUBZILKMSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- QMKFDEUJGYNFMC-AVGNSLFASA-N Leu-Pro-Arg Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QMKFDEUJGYNFMC-AVGNSLFASA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 1
- KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- PQPMMGQTRQFSDA-SRVKXCTJSA-N Met-Glu-His Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O PQPMMGQTRQFSDA-SRVKXCTJSA-N 0.000 description 1
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 1
- CMHTUJQZQXFNTQ-OEAJRASXSA-N Phe-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O CMHTUJQZQXFNTQ-OEAJRASXSA-N 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 description 1
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 1
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 1
- PVDTYLHUWAEYGY-CIUDSAMLSA-N Ser-Glu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PVDTYLHUWAEYGY-CIUDSAMLSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- FKAPNDWDLDWZNF-QEJZJMRPSA-N Trp-Asp-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FKAPNDWDLDWZNF-QEJZJMRPSA-N 0.000 description 1
- CZSMNLQMRWPGQF-XEGUGMAKSA-N Trp-Gln-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CZSMNLQMRWPGQF-XEGUGMAKSA-N 0.000 description 1
- GFJXBLSZOFWHAW-JYJNAYRXSA-N Tyr-His-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GFJXBLSZOFWHAW-JYJNAYRXSA-N 0.000 description 1
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- YTUABZMPYKCWCQ-XQQFMLRXSA-N Val-His-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N YTUABZMPYKCWCQ-XQQFMLRXSA-N 0.000 description 1
- PHZGFLFMGLXCFG-FHWLQOOXSA-N Val-Lys-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N PHZGFLFMGLXCFG-FHWLQOOXSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- VWSRWGFGAAKTQG-UHFFFAOYSA-N ammonium benzoate Chemical compound [NH4+].[O-]C(=O)C1=CC=CC=C1 VWSRWGFGAAKTQG-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- MDUBPQGQPBQGGN-UHFFFAOYSA-N azanium;2-methylpropanoate Chemical compound [NH4+].CC(C)C([O-])=O MDUBPQGQPBQGGN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 208000006685 tubal pregnancy Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to one kind of CpG-containing single-stranded deoxynucleotide capable of strengthening the immunostimulation of antigen or antigen composite, the vaccine composition of the single-stranded deoxynucleotide and antigen or antigen composite and its preparation process. The CpG-containing single-stranded deoxynucleotide can strengthen the specific antitumor, antiviral and chlamydia infection resisting activity of heat shock protein-antigen peptide fusion protein induced antigen peptide. In addition, the present invention also relates to the application of the CpG-containing single-stranded deoxynucleotide in preparing vaccine composition and the method of strengthening the immunostimulation. The vaccine composition may be used as treating medicine for viral infection, bacterial infectio, parasite infection, allergic reaction, cancer and relevant diseases.
Description
Technical field
The present invention relates to a kind of can enhancement antigen or the single chain deoxynucleotide that contains CpGODN of antigen composition immunostimulation, and by described single chain deoxynucleotide and antigen or vaccine composition that antigen composition is formed.In addition, the invention still further relates to the application of single chain deoxynucleotide in the preparation vaccine composition that contains CpGODN, and described vaccine composition is as the application of medicine.
Background technology
1984, discovery bacille Calmette-Guerin vaccine (BCG) DNA such as Tokunaga T can suppress growth of tumor, activate human peripheral blood single nucleus cell and NK cell (NK) cell, inducement interferon (IFN), these functions depend on CpG structure (Tokunaga T in the dna molecular, Antitumor activity of deoxyribonucleic acid fractionfrom Mycobacterium bovis BCG.I.Isolation, physicochemicalcharacterization, and antitumor activity, JNCI, 72:955.1984).CpG is the dinucleotides that is connected into by phosphoric acid by cytosine(Cyt) and guanine., wherein C represents cytosine(Cyt), and G represents guanine, and p represents phosphoric acid, and cytosine(Cyt) is positioned at 5 ' end.Studies show that in recent years, the oligonucleotide single stranded DNA that contains one or more CpG (CpG ODN) of synthetic also can show immunoregulation effect, can strengthen the activity of B cell, T cell, NK cell, antigen presenting cell (as monocyte, scavenger cell and dendritic cell) and neutrophil leucocyte, and show tangible potential applicability in clinical practice (Weiner GJ, The immunobiology and clinicalpotential of immunostimulatory CpG oligodeoxynucleotides.J Leukoc Biol 2000Oct; 68 (4): 455-63).But because the difference of sequence, CpG ODN can have diversified form.
(heat shock protein is to be present in the intravital molecular chaperone protein matter family of multiple biology HSP) to heat shock protein(HSP).In the process of immunne response, heat shock protein(HSP) can show following four kinds of basic functions: 1, carry antigen and enter the antigen presenting cell that comprises dendritic cell; 2, guiding antigen to enter the processing of MHC I classpath in antigen presenting cell offers; 3, stimulate the antigen presenting cell that comprises dendritic cell to express collaborative stimulation molecule, secrete cytokines; 4, make the antigen that carries antigen and heat shock protein(HSP) formation mixture or fusion rotein, to obtain character (the Tamura Y of activation antigen specificity cell toxicity T lymphocyte, Peng P, LiuK, Daou M, Srivastava PK.Immunotherapy of tumors with autologoustumor-derived heat shock protein preparations.Science 1997 Oct3; 278 (5335): 117-20).
(cytotoxic T lymphocyte CTL) is an individual killing tumor cell the most powerful and the immunocyte that kills and wounds virus infected cell to cytotoxic T lymphocyte.Ectogenic protein antigen is after using individuality, in comprising the antigen presenting cell of dendritic cell, mainly offer through the processing of MHC II classpath, excite humoral immune reaction (Heikema A, Agsteribbe E, Wilschut J, Huckriede A.Generation ofheat shock protein-based vaccines by intracellular loading of gp96 withantigenic peptides.Immunol Lett 1997 Jun 1; 57 (1-3): 69-74), can not induce antigen-specific CTL effectively.
Mycobacterium heat shock protein 65 can carry with its fusion or bonded or link coupled antigen peptide enter MHC I class angtigen presentation approach, the cytotoxic T lymphocyte of activation antigen peptide specific kills and wounds the tumour cell of antigen expressed peptide.
Hepatitis C virus (HCV) is the pathogenic agent that causes hepatitis C, has infected about more than 100,007,000 ten thousand people in the whole world.Liver cancer and liver cirrhosis are that HCV infects two severe complications that cause.Worldwide, adopting alpha-interferon and virazole combined utilization is the method for treatment infection with hepatitis C virus, it is efficient to be about 40% (Jon Cohen.The Scientific Challenge of Hepatitis C.Science, 1999,285:26-30).Adopting tubercule bacillus heat shock protein(HSP) 65 (HSP65) and multi-epitope HCV cAg to merge formed fusion rotein mutually is a kind of genetically engineered recombinant protein vaccine (CN02122116.2, China) that hepatitis C is had prevention and therapeutic action.
Chlamydia trachomatis (Chlamydia Trachomatis, CT) be the endotrophic microorganism of franchise that does not move, can cause trachoma, inclusion conjunctivitis, genitourinary system, lymphogranuloma venereum, endometritis, salpingitis, pelvic inflammatory disease, tubal infertility and fallopian tube ectopic pregnancy the mankind.
The major outer membrane albumen (MOMP) of chlamydia trachomatis can stimulate protective immunity.Adopting tubercule bacillus heat shock protein(HSP) 65 and chlamydia trachomatis major outer membrane albumen epitope antigen peptide to merge formed fusion rotein mutually is a kind of recombinant protein (CN02141977.9, China) that people's chlamydia trachomatis infection and relative disease thereof is had prevention and therapeutic action.
(Prostate specific antigen PSA) is a kind of tissure specific antigen that is expressed in prostate cancer cell to human prostate-specific antigen.Adopting tubercule bacillus heat shock protein(HSP) 65 and PSA epitope antigen peptide to merge formed fusion rotein mutually is a kind of recombinant protein (CN01134935.2, China) that human prostata cancer is had prevention and therapeutic action.
MUC1 albumen is a kind of of Saliva Orthana (mucins), and high level expression is the target spot of immunotherapy at mammary cancer, ovarian cancer, lung cancer, prostate cancer, colorectal cancer cell.Adopting tubercule bacillus heat shock protein(HSP) 65 and MUC1 antigen peptide to merge formed fusion rotein mutually is a kind of recombinant protein (CN01102614.6, China) that the expression proteic tumour of MUC1 (including but not limited to mammary cancer) is had prevention and therapeutic action.
HER-2 albumen (HER-2) is a kind of and EGF-R ELISA (Tadashi Yamamoto, et al.Similarity of protein encoded by the human c-erbB-2gene to epidermal growthfactor receptor.Nature vol 319 16 January 1986,230-234) has the transmembrane protein of very high homology, overexpression in HBT's cell of 30% is the target spot of mammary cancer immunotherapy.Adopting tubercule bacillus heat shock protein(HSP) 65 and HER-2 antigen peptide to merge formed fusion rotein mutually is a kind of recombinant protein (CN01136347.9, China) that human breast carcinoma is had prevention and therapeutic action.
Above-mentioned result of study shows, CpG ODN is had broad prospects with antigen or the antigen composition combined utilization that heat shock protein(HSP) merges mutually.Yet,, do not see relevant bibliographical information or open by till the present invention.
Summary of the invention
One of purpose of the present invention provides can enhancement antigen or the single chain deoxynucleotide that contains CpG of antigen composition immunostimulation, and its adjuvant that can be used as antigen or antigen composition comes the immunostimulation of enhancement antigen or antigen composition.They are made of the oligonucleotide single strand dna that contains one or more CpG, and its phosphodiester bond can be partial vulcanization, and all sulfurized also can be unvulcanized.
The single chain deoxynucleotide of the CpG of containing of the present invention comprises the sequence that is selected from following formula at least: (1) (G)
n(L)
nX
1+ X
2CGY
1Y
2(M)
n(G)
n, X wherein
1Be A, T or G; X
2Be A or T; Y
1Be A or T; Y
2Be A, T or C; L and M are respectively A, T, C or G; N is the integer of 0-6;
Preferably, the single chain deoxynucleotide that contains CpG has and is selected from following sequence shown in arbitrary:
5’-ggggTCgTTCgTCgTTgggggg-3’(SEQ ID NO：2)
5’-ggggATAACgTTgCgggggg-3’(SEQ ID NO：3)
5’-ggggTgCAACgTTCAgggggg-3’(SEQ ID NO：4)
5’-ggggTCCTACgTAggAgggggg-3’(SEQ ID NO：8)
5’-ggggTCCATgACgTTCCTgAAgggggg-3’(SEQ ID NO：23)
5’-gggggACgTCgCCggggggg-3’(SEQ ID NO：37)
5’-ggATCCgTACgCATgggggg-3’(SEQ ID NO：38)
5’-gggggAATCgATTCgggggg-3’(SEQ ID NO：101)
5’-gggATgCATCgATgCATCgggggg-3’(SEQ ID NO：100)
5’-ggTgCgACgTCgCAgggggg-3’(SEQ ID NO：102)
5’-gggACgTACgTCgggggg-3’(SEQ ID NO：105)
5’-gggggATCgACgTCgATCgggggg-3’(SEQ ID NO：108)
5’-ggCgATCgATCgATCggggggg-3’(SEQ ID NO：111)
5’-ggggTCgATCgATCgAgggggg-3’(SEQ ID NO：112)
5’-ggTCgCgATCgCgAgggggg-3’(SEQ ID NO：114)
5’-ggGGTCAACGTTGAgggggG-3’(SEQ ID NO：128)
5’-gTCgTTTTCgTCgACgAATTgggggggg-3’(SEQ ID NO：164)
5’-gTCgTTATCgTTTTTTCgTAgggggg-3’(SEQ ID NO：165)
5’-ggCgTTAACgACgggggg-3’(SEQ ID NO：166)
5’-gTCggCACgCgACgggggg-3’(SEQ ID NO：52)
5’-ggTgCgACgTCgCAgggggg-3’(SEQ ID NO：160)
5’-gTCTATTTTgTACgTACgTgggg-3’(SEQ ID NO：169)
5’-gACgTCgACgTCgACgTCAggggg-3’(SEQ ID NO：170)
5’-ggggTCgATCgTTgCTAgCgggggg-3’(SEQ ID NO：173)
5’-gggggACgTTATCgTATTggggggg-3’(SEQ ID NO：174)
5’-ggggTCgTCgTTTgTCgTgTgTCgTTgggggg-3’(SEQ ID NO：175)
5’-ACgATCgATCgATCgggggg-3’(SEQ ID NO：180)
5’-AgACgTCTAACgTCggggg-3’(SEQ ID NO：168)
5’-ggggTgCTggCCgTCgTTgggggg-3’(SEQ ID NO：5)
5’-ggggTCgTTgCCgTCgggggg-3’(SEQ ID NO：6)
5’-ACCggTATCgATgCCggTgggggg-3’(SEQ ID NO：22)
5’-TTCgTTgCATCgATgCATCgTTgggggg-3’(SEQ ID NO：28)
(2) (G)
n(L)
nCG (XY)
nCG (M)
n(G)
n, wherein X is A or T; Y is A or T; L and M are respectively A, T, C or G; N is the integer of 0-6;
The single chain deoxynucleotide that preferably contains CpG has and is selected from following sequence shown in arbitrary:
5’-ggggACgATACgTCggggggg-3’(SEQ ID NO：1)
5’-ggggACgATATCgATgggggg-3’(SEQ ID NO：7)
5’-ggACgATCgATCgTgggggg-3’(SEQ ID NO：99)
5’-TCggggACgATCgTCgggggg-3’(SEQ ID NO：106)
5’-gggggATCgATATCgATCgggggg-3’(SEQ ID NO：107)
5’-ggATCgATCgATCgATgggggg-3’(SEQ ID NO：110)
5’-ggTgCATCgATCgATgCAgggggg-3’(SEQ ID NO：109)
5’-ggTgCATCgTACgATgCAgggggg-3’(SEQ ID NO：104)
5’-ggTgCgATCgATCgCAgggggg-3’(SEQ ID NO：113)
5’-gggggggTCgATCgATgggggg-3’(SEQ ID NO：171)
5’-ggggTCgTCgAACgTTgggggg-3’(SEQ ID NO：172)
5’-TgTCgTTCCTTgTCgTT-3’(SEQ ID NO：16)
5’-TTCgCTTCgCTTTTCgCTTCgCTT-3’-3’(SEQ ID NO：29)
5’-ACCgCCAAggAgAAgCCgCAggAggg-3’(SEQ ID NO：44)
5’-TACAACggCgAggAATACC-3’(SEQ ID NO：46)
5’-gTACAACggCgAggAATACCT-3’(SEQ ID NO：48)
5’-ACCgTCgTTgCCgTCggCCC-3’(SEQ ID NO：49)
5’-TgCTggCCgTCgTT-3’(SEQ ID NO：50)
5’-gTCggCACgCgACg-3’(SEQ ID NO：51)
5’-gTCggCACgCgACgCCCCCC-3’(SEQ ID NO：53)
5’-TCCCgCTggACgTT-3’(SEQ ID NO：68)
5’-TTACCggTTAACgTTggCCggCC-3’(SEQ ID NO：75)
5’-ACCggTTAACgTTgTCCCCgggg-3’(SEQ ID NO：76)
5’-CgTTgACgATCgTCCCATggCggg-3’(SEQ ID NO：88)
5’-TCTgCggCCTTCgTCg-3’(SEQ ID NO：89)
5’-TAgTAACCggTCCggCgCCCCC-3’(SEQ ID NO：90)
5’-TTgCAgCgCTgCCggTggg-3’(SEQ ID NO：91)
5’-CggCCCATCgAgggCgACggC-3’(SEQ ID NO：93)
5’-TCATCgACTCTCgAgCgTTC-3’(SEQ ID NO：117)
5’-ATCgTCgACTCTCgTgTTCTC-3’(SEQ ID NO：118)
5’-TgCAgCTTgCTgCTTgCTgCTTC-3’(SEQ ID NO：127)
5’-ggTgCgACgTCgCAgATgAT-3’(SEQ ID NO：136)
5’-ggTCgAACgTTCgAgATgAT-3’(SEQ ID NO：137)
5’-gggggCgTCgTTTTCgTCgACgAATT-3’(SEQ ID NO：143)
5’-actcgagacgcccgttgatagctt-3’(SEQ ID NO：145)
5’-AACgTTggCgTCgACgTCAgCgCC-3’(SEQ ID NO：146)
5’-gACgTCgACgTTgACgCT-3’(SEQ ID NO：147)
5’-ggCgTTAACgTTAgCgCT-3’(SEQ ID NO：148)
5’-AgCgCTAgCgCTgACgTT-3’(SEQ ID NO：149)
5’-CTAgACgTTCAAgCgTT-3’(SEQ ID NO：150)
5’-gACgATCgTCgACgATCgTC-3’(SEQ ID NO：156)
5’-gTCgTTCgTAgTCgACTACgAgTT-3’(SEQ ID NO：161)
5’-AAAAgACgTCgACgTCgACgTCTTTT-3’(SEQ ID NO：162)
5’-TgCgACgATCgTCgCACgATCggAT-3’(SEQ ID NO：176)
5’-TgCgACgTCgCACAgCgT-3’(SEQ ID NO：177)
(3) (TCG)
n(L)
nCG (M)
n(G)
n, wherein L and M are respectively A, T, C or G; N is the integer of 0-6;
Preferably, the single chain deoxynucleotide that contains CpG has and is selected from following sequence shown in arbitrary:
5’-TCgTTgCCgTCgg-3’(SEQ ID NO：59)
5’-TCgTTgCCgTCggg-3’(SEQ ID NO：60)
5’-TCgTTgCCgTCgggg-3’(SEQ ID NO：61)
5’-TCgTTgCCgTCggggg-3’(SEQ ID NO：62)
5’-TCgTTgCCgTCgggggg-3’(SEQ ID NO：63)
5’-TCgTTgCCgTCggggggg-3’(SEQ ID NO：64)
5’-TCgTTgCCgTCgggggggg-3’(SEQ ID NO：65)
5’-TCgTTgCCgTCggggggggg-3’(SEQ ID NO：66)
5’-TCgTCgggTgCATCgATgCAgggggg-3’(SEQ ID NO：103)
5’-TCgTCgggTgCAACgTTgCAgggggg-3’(SEQ ID NO：129)
5’-TCgTCgggTgCgTCgACgCAgggggg-3’(SEQ ID NO：130)
5’-TCgTCgggTgCgATCgCAgggggg-3’(SEQ ID NO：131)
5’-TCgTCgggTgCgACgATCgTCgCAgggggg-3’(SEQ ID NO：132)
5’-TCgTCgTgCgACgTCgCAgggggg-3’(SEQ ID NO：133)
5’-TCgTCgCAgAACgTTCTgggggg-3’(SEQ ID NO：134)
5’-TCgTgCgACgTCgCAgggggg-3’(SEQ ID NO：135)
5’-TCgTgCgACgATCgTCgCAgggggg-3’(SEQ ID NO：139)
5’-TCgTATgCATCgATgCATAgggAgg-3’(SEQ ID NO：140)
5’-TCgTgCATCgATgCAgggggg-3’(SEQ ID NO：157)
5’-TCgAAACgTTTCgggggg-3’(SEQ ID NO：158)
5’-TCggACgATCgTCgggggg-3’(SEQ ID NO：159)
5’-TCgAgCgATCgCTCgAgggggg-3’(SEQ ID NO：179)
5’-TCgTCgCTTTgTCgTTgggg-3’(SEQ ID NO：13)
5’-TCgTCgTTTTgTCgTTgggg-3’(SEQ ID NO：11)
5’-TCgTCgggTgCgACgTCgCAgggggg-3’(SEQ ID NO：18)
5’-TCgTCgggTgCgACgATCgTCgggggg-3’(SEQ ID NO：19)
5’-TCgTCgTTTgCATCgATgCAggggggg-3’(SEQ ID NO：21)
5’-TCgTCgTTTTgACgATCgTCgggggg-3’(SEQ ID NO：24)
5’-TCgTTCggggTgCCg-3’(SEQ ID NO：80)
5’-TCgTTCggggTACCgATgggg-3’(SEQ ID NO：84)
5’-TCgTTgCgCTCCCATgCCgggggg-3’(SEQ ID NO：85)
5’-TCgTCgTTTCgTCgTTgggg-3’(SEQ ID NO：86)
5’-TCgTTgTCgTTTCgCTgCCggCggggg-3’(SEQ ID NO：87)
5’-TgCTTgggTggCAgCTgCCAgggggg-3’(SEQ ID NO：125)
5’-TgCTgCTTTgCTgCTTgggg-3’(SEQ ID NO：126)
5’-AACgTTCgACgTCgAACggggggg-3’(SEQ ID NO：163)
5’-AACgACgACgTTggggg-3’(SEQ ID NO：167)
(4) (TCG)
n(L)
nX
1X
2CG (M)
n, X wherein
1Be A, T or G; X
2Be A or T; L and M are respectively A, T, C or G; N is the integer of 0-6;
Preferably, the single chain deoxynucleotide that contains CpG has and is selected from following sequence shown in arbitrary:
5’-TCgTAACgTTgTTTTTAACgTT-3’(SEQ ID NO：9)
5’-TCgTCgTATACgACgATCgTT-3’(SEQ ID NO：10)
5’-TCgTCgTTTgCgTTgTCgTT-3’(SEQ ID NO：12)
5’-TCCTgTCgTTTTgTCgTT-3’(SEQ ID NO：14)
5’-TCgTCgTTgTCgTTCgCT-3’(SEQ ID NO：15)
5’-TCgTCgTTACCgATgACgTCgCCgT-3’(SEQ ID NO：17)
5’-TCgTCgTTTgCATCgATgCAgTCgTCgTT-3’(SEQ ID NO：20)
5’-TCgCCTCgTCgCCTTCgAgC-3’g-3’(SEQ ID NO：30)
5’-TCgTgTgCgTgCCgTTggg-3’T-3’(SEQ ID NO：31)
5’-TCgTCgAgggCgCCggTgAC-3’-3’(SEQ ID NO：32)
5’-TCgTCgCCggTgggggTgTg-3’3’(SEQ ID NO：33)
5’-TCgTCgTACgCAATTgTCTT-3’3’(SEQ ID NO：34)
5’-TCgCCCACCggTgggggggg-3’3’(SEQ ID NO：35)
5’-TCgTCgCAgACCggTCTgggg-3’(SEQ ID NO：36)
5’-TCgTCgCggCCggCgCCCCC-3’(SEQ ID NO：39)
5’-TCgTCgCggCCgCgAggggg-3’(SEQ ID NO：40)
5’-TCgAggACAAgATTCTCgTgC-3’(SEQ ID NO：41)
5’-TCgAggACAAgATTCTCgTgCAggCC-3’(SEQ ID NO：42)
5’-TCgTgCAggCCAACgAggCCg-3’(SEQ ID NO：43)
5’-TCgTTgCCgTCggCCC-3’(SEQ ID NO：45)
5’-TCggCACgCgACgTgCTggCCgTCgTTTCC-3’(SEQ ID NO：47)
5’-TCgTTgCCgTCggCCCCCCCCC-3’(SEQ ID NO：54)
5’-TCgTTgCCgTCggCCCCCC-3’(SEQ ID NO：55)
5’-TCgTTgCCgTCggCCCCC-3’(SEQ ID NO：56)
5’-TCgTTgCCgTCggCCCC-3’(SEQ ID NO：57)
5’-TCgTTgCCgTCggCCCCCCC-3’(SEQ ID NO：58)
5’-TCgAggACAAgATTCTCgT-3’(SEQ ID NO：67)
5’-TCggCACgCgACgTgCTggCCgTCgTT-3’(SEQ ID NO：69)
5’-TCgTCgCgCCgTCACgggggg-3’(SEQ ID NO：70)
5’-TCgTgTgCgTgCCgTTggg-3’(SEQ ID NO：71)
5’-TCgTCgCCgTTgggCggg-3’(SEQ ID NO：72)
5’-TCgTCgACgTCgTTgggCggg-3’(SEQ ID NO：73)
5’-TCgCAgTTgTCgTAACgTTgggCggg-3’(SEQ ID NO：74)
5’-TCgTCgTTggTATgTT-3’(SEQ ID NO：77)
5’-TCgTCgTCgTCgTTgTCgTT-3’(SEQ ID NO：78)
5’-TCgTCgTCgTCgTTgTCgTTgggg-3’(SEQ ID NO：79)
5’-TCgTTCggggTgCCg-3’(SEQ ID NO：80)
5’-TCgTTCggggTAACgATT-3’(SEQ ID NO：81)
5’-TCgTTCggggTAACgTT-3’(SEQ ID NO：82)
5’-TCgTTCggggTACCgAT-3’(SEQ ID NO：83)
5’-TCgTACggCCgCCgTACggCggg-3’(SEQ ID NO：92)
5’-TCgCgTCgACTCCCCTCgAgggg-3’(SEQ ID NO：94)
5’-TCgTCgTCgACTCgTggTCggggg-3’(SEQ ID NO：95)
5’-TCgggCgCCCgATCgggggg-3’(SEQ ID NO：96)
5’-TCgTCggTCTTTCgAAATT-3’(SEQ ID NO：97)
5’-TCgTgACgTCCTCgAgTT-3’(SEQ ID NO：98)
5’-TCgTCTTTCgACTCgTTCTC-3’(SEQ ID NO：115)
5’-TCgTCgTTTTgCgTTCTC-3’(SEQ ID NO：116)
5’-TCgACTTTCgTCgTTCTgTT-3’(SEQ ID NO：119)
5’-TCgTCgTTTCgTCgTTCTC-3’(SEQ ID NO：120)
5’-TCgTCgTCgTCgTTgTCgTT-3’(SEQ ID NO：121)
5’-TCgTTCTCgACTCgTTCTC-3’(SEQ ID NO：122)
5’-TCgACgTTCgTCgTTCgTCgTTC-3’(SEQ ID NO：123)
5’-TCgTCgACgTCgTTCgTTCTC-3’(SEQ ID NO：124)
5’-TCgTgCgACgTCgCAgATgAT-3’(SEQ ID NO：138)
5’-TCgTCgAgCgCTCgATCggAT-3’(SEQ ID NO：141)
5’-TCgTCgTTTCgTAgTCgTTgACgTCggg-3’(SEQ ID NO：142)
5’-TCgTCggACgTTTTCCgACgTTCT-3’(SEQ ID NO：144)
5’-TCgTCgTTTTCgTCgTTTTCgTCgTT-3’(SEQ ID NO：151)
5’-TCgTCgTTTgTCgTgTgTCgTT-3；(SEQ ID NO：152)
5’-TCgTCgTTggTCggggTCgTTggggTCgTT-3’(SEQ ID NO：153)
5’-TCgTCgTTTCgTCTCTCgTT-3’(SEQ ID NO：154)
5’-TCgTCgTTTTgCTgCgTCgTT-3’(SEQID NO：155)
5’-TCgAgCgTTTTCgCTCgAATT-3’(SEQ ID NO：178)
(5) comprise the sequence of TTCGTCG.
Preferably, the single chain deoxynucleotide that contains CpG has and is selected from following sequence shown in arbitrary:
5’-TTCgTCgTTTgATCgATgTTCgTTgggggg-3’(SEQ ID NO：25)’
5’-TTCgTCgTTgTgATCgATgggggg-3’-3’(SEQ ID NO：26)
5’-TATCgATgTTTTCgTCgTCgTTgggggg-3’(SEQ ID NO：27)
5’-TCgACTTTCgTCgTTCTgTT-3’(SEQ ID NO：119)
5’-TCgTCgTTTCgTCgTTCTC-3’(SEQ ID NO：120)
5’-TCgACgTTCgTCgTTCgTCgTTC-3’(SEQ ID NO：123)
5’-TCgTCgTTTTCgTCgTTTTCgTCgTT-3’(SEQ ID NO：151)
The single chain deoxynucleotide of the CpG of containing of the present invention also comprises the modification of each group on the base in the single chain deoxynucleotide, wherein said modification comprises that non-thio-modification, thio-modification, part thio-modification, rare base modification (dI, dU etc.), the modification that methylates, sulfydryl, Aminolinker C6 or Thiol-C6 S-S etc. are used for and the applied modification mode of other material couplings.
Another object of the present invention provides the vaccine composition of being made up of above-mentioned single chain deoxynucleotide and antigen or antigen composition, wherein the preferred of antigen or antigen composition is mixture or the fusion rotein that is formed by mycobacterium heat shock protein 65 and antigen peptide, and this mixture or fusion rotein can induce the preparation of antigen-specific CTL.Described antigen peptide is meant to have immunogenic peptide section or form under mixture, coupled thing or the fusion rotein state at the protein with other to have immunogenic peptide section, for example: the multi-epitope core antigen of C type hepatitis virus antigen peptide among the CN02122116.2, the relative disease that this antigen peptide causes infection with hepatitis C virus and infection with hepatitis C virus has prevention and therapeutic action, and concrete sequence is as follows:
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Glu Ile Asp
Asp Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro
Leu Glu Asp Ser Glu Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro
Arg Leu Gly Val Arg Ala Glu Asn Asp Glu Ile Glu Gly Pro Arg
Leu Gly Val Arg Ala Thr Arg Lys Thr Ser Glu Arg Asn Asp Glu
Leu Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln
Glu Ile Asp Asn Glu
Chlamydia trachomatis among the CN02141977.9 is mainly the multi-epitope antigen polypeptide, the effect that it has treatment and prevent the relative disease that is caused by chlamydozoan and choamydiae infection, and concrete sequence is as follows:
Glu Phe Pro Ala Tyr Gly Arg His Met Gln Asp Ala Glu Met Phe Thr
Asn Ala Ala Cys Met Ala Leu Asn Ile Trp Asp Glu Leu Asn Val Leu
Cys Asn Ala Ala Glu Phe Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly
Lys Glu Phe Pro Leu Ala Leu Asp Ala Ala Thr Gly Thr Lys Asp Ala
Ser Ile Asp Tyr His Glu Trp Gln Ala Ser Leu Ala Leu Ser Tyr Arg
Leu Asn Met Phe Thr Pro Tyr Ile Gly Val Lys Trp Ser Arg Ala Ser
Phe Asp Ala Asp Thr Tyr Lys Leu
Single copy antigenic peptide of the human prostate-specific cell antigen toxic T lymphocyte multi-epitope among the CN01134935.2, its prostate cancer to the people has the effect of prevention and treatment, and concrete sequence is as follows:
Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His Val Ile Ser
Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr Lys
MUC1 cell antigen toxic T lymphocyte epitope antigen peptide among the CN011026146, it includes but not limited to that to the tumour of expressing MUC1 mammary cancer, ovarian cancer, lung cancer, prostate cancer, colorectal cancer cell etc. have the effect of prevention and treatment, and concrete sequence is as follows:
Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp
Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val
Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu
Multi-epitope HER-2 antigen peptide among the CN011363479, it includes but not limited to that to the tumour of expressing HER-2 mammary cancer, ovarian cancer, cancer of the stomach, carcinoma of endometrium, salivary-gland carcinoma, gland cancer, preceding gland cancer, colon and the rectum cancer, nonsmall-cell lung cancer, adenocarcinoma of lung etc. have the effect of treatment and prevention, and concrete sequence is as follows:
Met Glu His Leu Arg Glu Val Arg Ala Val Thr Ser Ala Asn Ile Gln
Glu Phe Ala Gly Cys Lys Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro
Glu Ser Phe Asp Gly Asp Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro
Glu Gln Leu Gln Val Phe Glu Thr Leu Glu Glu Ile
Another object of the present invention is to provide a kind of method of producing vaccine composition, comprise that the single chain deoxynucleotide that contains CpG with significant quantity mixes with the antigen or the antigen composition of significant quantity.Preferably the single chain deoxynucleotide that contains CpG with significant quantity mixes mutually with the mixture or the fusion rotein that are formed by mycobacterium heat shock protein 65 and antigen peptide of significant quantity.
Another aspect of the present invention provides the method for a kind of enhancement antigen or antigen composition immunostimulation, and it is to unite use with containing the single chain deoxynucleotide of CpG and antigen or antigen composition.
Result of study of the present invention shows, when the single chain deoxynucleotide that contains CpG mixes use with mixture that is formed by mycobacterium heat shock protein 65 and antigen peptide or fusion rotein, the single chain deoxynucleotide that contains CpG can significantly strengthen the activity that mycobacterium heat shock protein 65 antigen peptide fusion roteins induce the antigen peptide specific CTL, significantly strengthening mycobacterium heat shock protein 65 antigen peptide fusion roteins stimulates mouse to suppress the activity of antigen expressed peptide growth of tumour cell, and significantly strengthening mycobacterium heat shock protein 65 antigen peptide fusion roteins, to induce antigen peptide specific antitumor, the activity of antiviral and anti-choamydiae infection.
The vaccine composition that provides on the one hand more of the present invention is used for the treatment of application in the vaccine of virus infection, infectation of bacteria, parasitic infection, transformation reactions or cancer in preparation.Comprise and to grant the people or the Mammals of needs treatment by the immune composition that the single chain deoxynucleotide that contains CpG and antigen or antigen composition are formed.The relative disease that described virus infection, infectation of bacteria, parasitic infection, transformation reactions or cancer include but are not limited to: to be caused by infection with hepatitis C virus, the relative disease, prostate cancer, mammary cancer, ovarian cancer, lung cancer, cancer of the stomach, carcinoma of endometrium, salivary-gland carcinoma, gland cancer, colon and the rectum cancer that cause by chlamydozoan and choamydiae infection, nonsmall-cell lung cancer, adenocarcinoma of lung etc.
Embodiment
Below in conjunction with concrete preparation embodiment and biology effect embodiment, the present invention is described in further detail.Should be understood that these embodiment just in order to demonstrate the invention, but not limit the scope of the invention by any way.
In following embodiment, various processes of Xiang Ximiaoshuing and method are not ordinary methods as known in the art, and for example synthetic employing solid phase phosphoramidite triester method, ELISA adopt indirect method.
In following embodiment, the source of agents useful for same, trade(brand)name and/or be necessary to list its moiety person are all only indicated once.Do not giving unnecessary details foregoing if no special instructions at used identical reagent thereafter.
The design of embodiment 1 CpG single chain deoxynucleotide
Implementation sequence is as follows:
(1)(G)
n(L)
nX
1X
2CGY
1Y
2(M)
n(G)
n
X
1=A, T, G; X
2=A, T; Y
1=A, T; Y
2=A, T, C; L, M=A, T, C, G; N is 0-6
5’-ggggTCgTTCgTCgTTgggggg-3’(SEQ ID NO：2)
5’-ggggATAACgTTgCgggggg-3’(SEQ ID NO：3)
5’-ggggTgCAACgTTCAgggggg-3’(SEQ ID NO：4)
5’-ggggTCCTACgTAggAgggggg-3’(SEQ ID NO：8)
5’-ggggTCCATgACgTTCCTgAAgggggg-3’(SEQ ID NO：23)
5’-gggggACgTCgCCggggggg-3’(SEQ ID NO：37)
5’-ggATCCgTACgCATgggggg-3’(SEQ ID NO：38)
5’-gggggAATCgATTCgggggg-3’(SEQ ID NO：101)
5’-gggATgCATCgATgCATCgggggg-3’(SEQ ID NO：100)
5’-ggTgCgACgTCgCAgggggg-3’(SEQ ID NO：102)
5’-gggACgTACgTCgggggg-3’(SEQ ID NO：105)
5’-gggggATCgACgTCgATCgggggg-3’(SEQ ID NO：108)
5’-ggCgATCgATCgATCggggggg-3’(SEQ ID NO：111)
5’-ggggTCgATCgATCgAgggggg-3’(SEQ ID NO：112)
5’-ggTCgCgATCgCgAgggggg-3’(SEQ ID NO：114)
5’-ggGGTCAACGTTGAgggggG-3’(SEQ ID NO：128)
5’-gTCgTTTTCgTCgACgAATTgggggggg-3’(SEQ ID NO：164)
5’-gTCgTTATCgTTTTTTCgTAgggggg-3’(SEQ ID NO：165)
5’-ggCgTTAACgACgggggg-3’(SEQ ID NO：166)
5’-gTCggCACgCgACgggggg-3’(SEQ ID NO：52)
5’-ggTgCgACgTCgCAgggggg-3’(SEQ ID NO：160)
5’-gTCTATTTTgTACgTACgTgggg-3’(SEQ ID NO：169)
5’-gACgTCgACgTCgACgTCAggggg-3’(SEQ ID NO：170)
5’-ggggTCgATCgTTgCTAgCgggggg-3’(SEQ ID NO：173)
5’-gggggACgTTATCgTATTggggggg-3’(SEQ ID NO：174)
5’-ggggTCgTCgTTTgTCgTgTgTCgTTgggggg-3’(SEQ ID NO：175)
5’-ACgATCgATCgATCgggggg-3’(SEQ ID NO：180)
5’-AgACgTCTAACgTCggggg-3’(SEQ ID NO：168)
5’-ggggTgCTggCCgTCgTTgggggg-3’(SEQ ID NO：5)
5’-ggggTCgTTgCCgTCgggggg-3’(SEQ ID NO：6)
5’-ACCggTATCgATgCCggTgggggg-3’(SEQ ID NO：22)
5’-TTCgTTgCATCgATgCATCgTTgggggg-3’(SEQ ID NO：28)
(2)(G)
n(L)
nCG(XY)
nCG(M)
n(G)
n
X=A, T; Y=A, T; L, M=A, T, C, G; N is 0-6
5’-ggggACgATACgTCggggggg-3’(SEQ ID NO：1)
5’-ggggACgATATCgATgggggg-3’(SEQ ID NO：7)
5’-ggACgATCgATCgTgggggg-3’(SEQ ID NO：99)
5’-TCggggACgATCgTCgggggg-3’(SEQ ID NO：106)
5’-gggggATCgATATCgATCgggggg-3’(SEQ ID NO：107)
5’-ggATCgATCgATCgATgggggg-3’(SEQ ID NO：110)
5’-ggTgCATCgATCgATgCAgggggg-3’(SEQ ID NO：109)
5’-ggTgCATCgTACgATgCAgggggg-3’(SEQ ID NO：104)
5’-ggTgCgATCgATCgCAgggggg-3’(SEQ ID NO：113)
5’-gggggggTCgATCgATgggggg-3’(SEQ ID NO：171)
5’-ggggTCgTCgAACgTTgggggg-3’(SEQ ID NO：172)
5’-TgTCgTTCCTTgTCgTT-3’(SEQ ID NO：16)
5’-TTCgCTTCgCTTTTCgCTTCgCTT-3’-3’(SEQ ID NO：29)
5’-ACCgCCAAggAgAAgCCgCAggAggg-3’(SEQ ID NO：44)
5’-TACAACggCgAggAATACC-3’(SEQ ID NO：46)
5’-gTACAACggCgAggAATACCT-3’(SEQ ID NO：48)
5’-ACCgTCgTTgCCgTCggCCC-3’(SEQ ID NO：49)
5’-TgCTggCCgTCgTT-3’(SEQ ID NO：50)
5’-gTCggCACgCgACg-3’(SEQ ID NO：51)
5’-gTCggCACgCgACgCCCCCC-3’(SEQ ID NO：53)
5’-TCCCgCTggACgTT-3’(SEQ ID NO：68
5’-TTACCggTTAACgTTggCCggCC-3’(SEQ ID NO：75)
5’-ACCggTTAACgTTgTCCCCgggg-3’(SEQ ID NO：76)
5’-CgTTgACgATCgTCCCATggCggg-3’(SEQ ID NO：88)
5’-TCTgCggCCTTCgTCg-3’(SEQ ID NO：89)
5’-TAgTAACCggTCCggCgCCCCC-3’(SEQ ID NO：90)
5’-TTgCAgCgCTgCCggTggg-3’(SEQ ID NO：91)
5’-CggCCCATCgAgggCgACggC-3’(SEQ ID NO：93)
5’-TCATCgACTCTCgAgCgTTC-3’(SEQ ID NO：117)
5’-ATCgTCgACTCTCgTgTTCTC-3’(SEQ ID NO：118)
5’-TgCAgCTTgCTgCTTgCTgCTTC-3’(SEQ ID NO：127)
5’-ggTgCgACgTCgCAgATgAT-3’(SEQ ID NO：136)
5’-ggTCgAACgTTCgAgATgAT-3’(SEQ ID NO：137)
5’-gggggCgTCgTTTTCgTCgACgAATT-3’(SEQ ID NO：143)
5’-actcgagacgcccgttgatagctt-3’(SEQ ID NO：145)
5’-AACgTTggCgTCgACgTCAgCgCC-3’(SEQ ID NO：146)
5’-gACgTCgACgTTgACgCT-3’(SEQ ID NO：147)
5’-ggCgTTAACgTTAgCgCT-3’(SEQ ID NO：148)
5’-AgCgCTAgCgCTgACgTT-3’(SEQ ID NO：149)
5’-CTAgACgTTCAAgCgTT-3’(SEQ ID NO：150)
5’-gACgATCgTCgACgATCgTC-3’(SEQ ID NO：156)
5’-gTCgTTCgTAgTCgACTACgAgTT-3’(SEQ ID NO：161)
5’-AAAAgACgTCgACgTCgACgTCTTTT-3’(SEQ ID NO：162)
5’-TgCgACgATCgTCgCACgATCggAT-3’(SEQ ID NO：176)
5’-TgCgACgTCgCACAgCgT-3’(SEQ ID NO：177)
(3)(TCG)
n(L)
nCG(M)
n(G)
n
L, M=A, T, C, G; N is 0-6
5’-TCgTTgCCgTCgg-3’(SEQ ID NO：59)
5’-TCgTTgCCgTCggg-3’(SEQ ID NO：60)
5’-TCgTTgCCgTCgggg-3’(SEQ ID NO：61)
5’-TCgTTgCCgTCggggg-3’(SEQ ID NO：62)
5’-TCgTTgCCgTCgggggg-3’(SEQ ID NO：63)
5’-TCgTTgCCgTCggggggg-3’(SEQ ID NO：64)
5’-TCgTTgCCgTCgggggggg-3’(SEQ ID NO：65)
5’-TCgTTgCCgTCggggggggg-3’(SEQ ID NO：66)
5’-TCgTCgggTgCATCgATgCAgggggg-3’(SEQ ID NO：103)
5’-TCgTCgggTgCAACgTTgCAgggggg-3’(SEQ ID NO：129)
5’-TCgTCgggTgCgTCgACgCAgggggg-3’(SEQ ID NO：130)
5’-TCgTCgggTgCgATCgCAgggggg-3’(SEQ ID NO：131)
5’-TCgTCgggTgCgACgATCgTCgCAgggggg-3’(SEQ ID NO：132)
5’-TCgTCgTgCgACgTCgCAgggggg-3’(SEQ ID NO：133)
5’-TCgTCgCAgAACgTTCTgggggg-3’(SEQ ID NO：134)
5’-TCgTgCgACgTCgCAgggggg-3’(SEQ ID NO：135)
5’-TCgTgCgACgATCgTCgCAgggggg-3’(SEQ ID NO：139)
5’-TCgTATgCATCgATgCATAgggAgg-3’(SEQ ID NO：140)
5’-TCgTgCATCgATgCAgggggg-3’(SEQ ID NO：157)
5’-TCgAAACgTTTCgggggg-3’(SEQ ID NO：158)
5’-TCggACgATCgTCgggggg-3’(SEQ ID NO：159)
5’-TCgAgCgATCgCTCgAgggggg-3’(SEQ ID NO：179)
5’-TCgTCgCTTTgTCgTTgggg-3’(SEQ ID NO：13)
5’-TCgTCgTTTTgTCgTTgggg-3’(SEQ ID NO：11)
5’-TCgTCgggTgCgACgTCgCAgggggg-3’(SEQ ID NO：18)
5’-TCgTCgggTgCgACgATCgTCgggggg-3’(SEQ ID NO：19)
5’-TCgTCgTTTgCATCgATgCAggggggg-3’(SEQ ID NO：21)
5’-TCgTCgTTTTgACgATCgTCgggggg-3’(SEQ ID NO：24)
5’-TCgTTCggggTgCCg-3’(SEQ ID NO：80)
5’-TCgTTCggggTACCgATgggg-3’(SEQ ID NO：84)
5’-TCgTTgCgCTCCCATgCCgggggg-3’(SEQ ID NO：85)
5’-TCgTCgTTTCgTCgTTgggg-3’(SEQ ID NO：86)
5’-TCgTTgTCgTTTCgCTgCCggCggggg-3’(SEQ ID NO：87)
5’-TgCTTgggTggCAgCTgCCAgggggg-3’(SEQ ID NO：125)
5’-TgCTgCTTTgCTgCTTgggg-3’(SEQ ID NO：126)
5’-AACgTTCgACgTCgAACggggggg-3’(SEQ ID NO：163)
5’-AACgACgACgTTggggg-3’(SEQ ID NO：167)
(4)(TCG)
n(L)
nX
1X
2CG (M)
n
X
1=A, T, G; X
2=A, T; L, M=A, T, C, G; N is 0-6;
5’-TCgTAACgTTgTTTTTAACgTT-3’(SEQ ID NO：9)
5’-TCgTCgTATACgACgATCgTT-3’(SEQ ID NO：10)
5’-TCgTCgTTTgCgTTgTCgTT-3’(SEQ ID NO：12)
5’-TCCTgTCgTTTTgTCgTT-3’(SEQ ID NO：14)
5’-TCgTCgTTgTCgTTCgCT-3’(SEQ ID NO：15)
5’-TCgTCgTTACCgATgACgTCgCCgT-3’(SEQ ID NO：17)
5’-TCgTCgTTTgCATCgATgCAgTCgTCgTT-3’(SEQ ID NO：20)
5’-TCgCCTCgTCgCCTTCgAgC-3’g-3’(SEQ ID NO：30)
5’-TCgTgTgCgTgCCgTTggg-3’T-3’(SEQ ID NO：31)
5’-TCgTCgAgggCgCCggTgAC-3’-3’(SEQ ID NO：32)
5’-TCgTCgCCggTgggggTgTg-3’3’(SEQ ID NO：33)
5’-TCgTCgTACgCAATTgTCTT-3’3’(SEQ ID NO：34)
5’-TCgCCCACCggTgggggggg-3’3’(SEQ ID NO：35)
5’-TCgTCgCAgACCggTCTgggg-3’(SEQ ID NO：36)
5’-TCgTCgCggCCggCgCCCCC-3’(SEQ ID NO：39)
5’-TCgTCgCggCCgCgAggggg-3’(SEQ ID NO：40)
5’-TCgAggACAAgATTCTCgTgC-3’(SEQ ID NO：41)
5’-TCgAggACAAgATTCTCgTgCAggCC-3’(SEQ ID NO：42)
5’-TCgTgCAggCCAACgAggCCg-3’(SEQ ID NO：43)
5’-TCgTTgCCgTCggCCC-3’(SEQ ID NO：45)
5’-TCggCACgCgACgTgCTggCCgTCgTTTCC-3’(SEQ ID NO：47)
5’-TCgTTgCCgTCggCCCCCCCCC-3’(SEQ ID NO：54)
5’-TCgTTgCCgTCggCCCCCC-3’(SEQ ID NO：55)
5’-TCgTTgCCgTCggCCCCC-3’(SEQ ID NO：56)
5’-TCgTTgCCgTCggCCCC-3’(SEQ ID NO：57)
5’-TCgTTgCCgTCggCCCCCCC-3’(SEQ ID NO：58)
5’-TCgAggACAAgATTCTCgT-3’(SEQ ID NO：67)
5’-TCggCACgCgACgTgCTggCCgTCgTT-3’(SEQ ID NO：69)
5’-TCgTCgCgCCgTCACgggggg-3’(SEQ ID NO：70)
5’-TCgTgTgCgTgCCgTTggg-3’(SEQ ID NO：71)
5’-TCgTCgCCgTTgggCggg-3’(SEQ ID NO：72)
5’-TCgTCgACgTCgTTgggCggg-3’(SEQ ID NO：73)
5’-TCgCAgTTgTCgTAACgTTgggCggg-3’(SEQ ID NO：74)
5’-TCgTCgTTggTATgTT-3’(SEQ ID NO：77)
5’-TCgTCgTCgTCgTTgTCgTT-3’(SEQ ID NO：78)
5’-TCgTCgTCgTCgTTgTCgTTgggg-3’(SEQ ID NO：79)
5’-TCgTTCggggTgCCg-3’(SEQ ID NO：80)
5’-TCgTTCggggTAACgATT-3’(SEQ ID NO：81)
5’-TCgTTCggggTAACgTT-3’(SEQ ID NO：82)
5’-TCgTTCggggTACCgAT-3’(SEQ ID NO：83)
5’-TCgTACggCCgCCgTACggCggg-3’(SEQ ID NO：92)
5’-TCgCgTCgACTCCCCTCgAgggg-3’(SEQ ID NO：94)
5’-TCgTCgTCgACTCgTggTCggggg-3’(SEQ ID NO：95)
5’-TCgggCgCCCgATCgggggg-3’(SEQ ID NO：96)
5’-TCgTCggTCTTTCgAAATT-3’(SEQ ID NO：97)
5’-TCgTgACgTCCTCgAgTT-3’(SEQ ID NO：98)
5’-TCgTCTTTCgACTCgTTCTC-3’(SEQ ID NO：115)
5’-TCgTCgTTTTgCgTTCTC-3’(SEQ ID NO：116)
5’-TCgACTTTCgTCgTTCTgTT-3’(SEQ ID NO：119)
5’-TCgTCgTTTCgTCgTTCTC-3’(SEQ ID NO：120)
5’-TCgTCgTCgTCgTTgTCgTT-3’(SEQ ID NO：121)
5’-TCgTTCTCgACTCgTTCTC-3’(SEQ ID NO：122)
5’-TCgACgTTCgTCgTTCgTCgTTC-3’(SEQ ID NO：123)
5’-TCgTCgACgTCgTTCgTTCTC-3’(SEQ ID NO：124)
5’-TCgTgCgACgTCgCAgATgAT-3’(SEQ ID NO：138)
5’-TCgTCgAgCgCTCgATCggAT-3’(SEQ ID NO：141)
5’-TCgTCgTTTCgTAgTCgTTgACgTCggg-3’(SEQ ID NO：142)
5’-TCgTCggACgTTTTCCgACgTTCT-3’(SEQ ID NO：144)
5’-TCgTCgTTTTCgTCgTTTTCgTCgTT-3’(SEQ ID NO：151)
5’-TCgTCgTTTgTCgTgTgTCgTT-3；(SEQ ID NO：152)
5’-TCgTCgTTggTCggggTCgTTggggTCgTT-3’(SEQ ID NO：153)
5’-TCgTCgTTTCgTCTCTCgTT-3’(SEQ ID NO：154)
5’-TCgTCgTTTTgCTgCgTCgTT-3’(SEQ ID NO：155)
5’-TCgAgCgTTTTCgCTCgAATT-3’(SEQ ID NO：178)
(5) comprise the sequence of TTCGTCG
5’-TTCgTCgTTTgATCgATgTTCgTTgggggg-3’(SEQ ID NO：25)’
5’-TTCgTCgTTgTgATCgATgggggg-3’-3’(SEQ ID NO：26)
5’-TATCgATgTTTTCgTCgTCgTTgggggg-3’(SEQ ID NO：27)
5’-TCgACTTTCgTCgTTCTgTT-3’(SEQ ID NO：119)
5’-TCgTCgTTTCgTCgTTCTC-3’(SEQ ID NO：120)
5’-TCgACgTTCgTCgTTCgTCgTTC-3’(SEQ ID NO：123)
5’-TCgTCgTTTTCgTCgTTTTCgTCgTT-3’(SEQ ID NO：151)
Synthesizing of embodiment 2 CpG single chain deoxynucleotides
The synthetic advantages such as solid phase phosphoramidite triester method synthetic DNA fragment, this method has efficiently, quick coupling that adopt of DNA are extensive use of in the DNA chemosynthesis.
The DNA chemosynthesis is different from the DNA building-up process of enzymatic extends from 5 ' → 3 ' direction, but by 3 ' end beginning.Concrete reactions steps is as follows:
One, deprotection base
Slough the blocking group DMT (dimethoxytrityl) that is attached at the Nucleotide on the CpG (Controlled Pore Glass) with trichoroacetic acid(TCA), obtain free 5 '-hydroxyl terminal, for next step condensation reaction.
Two, activation
With the nucleotide monomer and the tetrazole activator mix of phosphoramidite protection and enter synthetic post; (its 3 '-end is activated to form phosphoramidite tetrazolium active intermediate; but 5 '-end is protected by DMT still), this intermediate will with the Nucleotide generation condensation reaction of the base of deprotection on the GpG.
Three, connect
When phosphoramidite tetrazolium active intermediate runs on the CpG the Nucleotide of deprotection base, will with its 5 '-hydroxyl generation affinity reaction, condensation is also sloughed tetrazolium, this moment, the synthetic oligonucleotide chain prolonged a base forward.
Four, sealing
For 5 ' of the reaction-hydroxyl that has neither part nor lot in that prevents to be connected on the CpG is extended, often seal this terminal hydroxy group by acetylize after the condensation reaction in circulating reaction subsequently, general acetylation reagent mixes formation with diacetyl oxide and N-Methylimidazole etc.
Five, oxidation
Nucleotide monomer is to be connected with oligonucleotide on being connected in CpG by inferior phosphide key during condensation reaction, and inferior phosphide key instability, easily by acid, basic hydrolysis, this moment, the tetrahydrofuran solution of iodine commonly used was converted into phosphotriester with inferior phosphinylidyne, obtained stable oligonucleotide.
Through after above five steps; a deoxynucleotide is just linked on the Nucleotide of CpG; after sloughing blocking group DMT on the deoxynucleotide 5 '-hydroxyl that newly connects with trichoroacetic acid(TCA) equally again, repeat above activation, connection, sealing, oxidising process and can obtain a dna fragmentation crude product.At last to its cut, the deprotection base (generally adopts the benzoyl protection to A, C base; The G base is protected with isobutyryl; The T base needn't be protected; Phosphorous acid is with nitrile ethyl protection), purifying (commonly used have HAP, PAGE, HPLC, C18, methods such as OPC), synthetic aftertreatment such as quantitative can obtain meeting the oligonucleotide fragment of requirement of experiment.
The solid phase synthesis oligonucleotide carries out on dna synthesizer; aforesaid method synthetic oligonucleotide is after sloughing protecting group; purpose oligonucleotide purity is extremely low; contain a large amount of impurity; phenylformic acid ammonia and isopropylformic acid ammonia that protecting group that major impurity is taken off to some extent and ammonia form; nitrile ethyl of taking off on the nitrile phosphorus base and the short chain that produces when synthetic etc. are to such an extent as to oligonucleotide content only is about 15% in the thick product.Although the efficient in each step is all 97%～98% when synthetic, cumulative efficient is not high.With chain length 20mer and 50mer is example, (97.5%) 20 ≈ 60%, (97.5%) 50 ≈ 28%, as seen purpose oligonucleotide content is very low in thick product, in addition 10% less than.These impurity especially are present in a large amount of salt and short chain in the thick product, cause quantitatively and are forbidden, and influence next step reaction, therefore must carry out purifying to oligonucleotide.Polyacrylamide gel electrophoresis (PAGE) purifying is adopted in suggestion, and the product purity height of this method purifying can be used for the molecular biology experiment of exhausted major part, can avoid many beyond thought troubles.If consider reduction of expenditure,,, then adopt desalting and purifying to get final product as simple PCR reaction for requiring lower experiment.
Oligonucleotide DNA is with OD
260Value is measured.In the 1cm of 1ml light path standard quartz cuvette, absorbancy is that 1 oligonucleotide solution is defined as 1OD under the 260nm wavelength
260Though for every kind of specific oligonucleotide, the composition of its base is not quite similar, the weight of 1260OD oligonucleotide DNA is about 33 μ g.
Embodiment 3 contains the enhancement of the single chain deoxynucleotide of CpG to heat shock protein(HSP) C hepatitis virus antigen peptide fusion protein immunostimulation
One, hepatitis C virus specific cytotoxic T lymphocyte fragmentation test
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and multi-epitope HCV cAg fusion rotein (HSP-HCV) contain the deoxy-oligonucleotide (CpG ODN) of CpG, the B16 cell (HCV of transfection HCV cAg multi-epitope antigen peptide gene
+The B16 cell).CpG ODN1(SEQ ID NO：7)，CpG ODN2(SEQ ID NO：106)，CpG ODN3(SEQ ID NO：103)，CpG ODN4(SEQ ID NO：18)，CpG ODN5(SEQ ID NO：86)，CpG ODN6(SEQ ID NO：79)，CpG ODN7(SEQ ID NO：95)，CpG ODN8(SEQ ID NO：123)，CpG ODN9(SEQ ID NO：124)，CpG ODN10(SEQ ID NO：159)。
2, laboratory animal and grouping:
40 of the male C57/BL6 mouse in employing 6-8 week, every group of 10 mouse, be divided into physiological saline group (injecting normal saline), HSP-HCV organizes (injecting 20 μ g HSP-HCV), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-HCV+CpG ODN organizes (injecting 20 μ g HSP-HCV, 50 μ g CpG ODN).HSP-HCV and CpGODN are mixed with desired concn with PBS respectively, and HSP-HCV+CpG ODN group is that HSP-HCV and CpGODN are mixed the back injection.
3, experimental technique
(1) injection
Used liquid, CpG ODN application liquid and HSP-HCV+CpG ODN mixed solution to each group injected in mice physiological saline, HSP-HCV respectively in the 1st, 14 and 21 day.
(2) preparation effector cell
At the 26th day mouse being taken off neck puts to death.Get mouse boosting cell or lymph-node cell according to a conventional method, the preparation single cell suspension.With the IMDM substratum re-suspended cell that contains 10%FBS, mouse Pi cell and conditioned medium and HSP-HCV (20 μ g/ml) that the ConA of adding 10% stimulates.37 ℃, 5%CO
2Cultivated 7 days.The results mouse boosting cell is the effector cell.
(3) preparation target cell
Adopt the IMDM culture medium culturing HCV of 10%FBS
+The B16 cell.With
51Cr mark HCV
+The B16 cell (at 37 ℃, 5%CO
2Cultivated 1 hour under the condition).With the IMDM washed cell that contains 10%FBS, totally three times.
(4) cellulotoxic experiment
Will
51Cr mark HCV
+The B16 cell joins in the hole of 96 well culture plates in the IMDM of 10%FBS substratum, and every hole 100 μ l contain 1 * 10
4Individual cell.Imitate target than adding effector cell (100 μ l) by 100: 1, establish three repeating holes.37 ℃, 5%CO
2Cultivated 4-6 hour.With centrifugal 5 minutes of 96 well culture plates (3000rpm).From every hole sucking-off 100 μ l supernatants, survey radioactivity.By following formula calculating effector cell's cytotoxic activity, represent with the specific killing rate.
The maximum spontaneous release rpm of rpm-that discharges of the spontaneous release rpm/ of specific killing rate (%)=experimental port rpm-
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 1-1CpG ODN induces the active enhancement of specific CTL to HSP65-HCV
| Group | Specific killing rate (%) |
| Physiological saline | 0.31±0.22 |
| HSP-HCV | 15.00±6.00 |
| CpG ODN1 | 0.51±0.33 |
| HSP-HCV+CpG ODN1 | 26.00±4.12 |
| CpGODN2 | 0.63±0.43 |
| HSP-HCV+CpG ODN2 | 27.32±3.23 |
| CpGODN3 | 1.02±0.56 |
| HSP-HCV+CpG ODN3 | 32.22±6.78 |
| CpG ODN4 | 0.88±0.54 |
| HSP-HCV+CpG ODN4 | 29.98±5.23 |
| CpGODN5 | 0.76±0.77 |
| HSP-HCV+CpG ODN5 | 35.00±3.89 |
| CpG ODN6 | 0.88±0.45 |
| HSP-HCV+CpG ODN6 | 34.98±5.03 |
| CpG ODN7 | 1.51±1.22 |
| HSP-HCV+CpG ODN7 | 31.34±6.65 |
| CpG ODN8 | 1.25±0.89 |
| HSP-HCV+CpG ODN8 | 27.75±5.65 |
| CpG ODN9 | 1.02±0.67 |
| HSP-HCV+CpG ODN9 CpG ODN10 HSP-HCV+CpG ODN10 | 37.21±6.24 0.98±0.56 32.78±5.32 |
5, conclusion:
The single chain deoxynucleotide that contains CpG can obviously strengthen the activity (p＜0.05) that the immunity of heat shock protein(HSP) C hepatitis virus antigen peptide fusion protein induces the specific cytotoxic T lymphocyte of HCV cAg.This CTL can kill and wound the cell that HCV infects in vivo.Therefore, the single chain deoxynucleotide that contains CpG can obviously strengthen antiviral (including but not limited to hepatitis C virus) activity of heat shock protein(HSP) C hepatitis virus antigen peptide fusion protein.
Two, kill and wound the experiment of HCV cells infected in the body
B16 cell (the HCV of transfection HCV cAg multi-epitope antigen peptide gene
+The B16 cell) can be used as the cell model (CN02122116.2) of infection with hepatitis C virus.Observe mouse and suppress the ability of this B16 cell growth, can detect that injection contains CpG single chain deoxynucleotide (CpG ODN) and tubercule bacillus heat shock protein(HSP) 65 multi-epitope HCV cAg fusion roteins stimulation mouse CTL kills and wounds the HCV infection cell activity in vivo.
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and multi-epitope HCV cAg fusion rotein (HSP-HCV) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (HCV of transfection HCV cAg multi-epitope antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
40 of the male C57/BL6 mouse in employing 6-8 week, every group 10, be divided into physiological saline group (injecting normal saline), HSP-HCV organizes (injecting 20 μ g HSP-HCV), CpG ODN group (injecting 50 μ g CpG ODN) and HSP-HCV+CpG ODN group (are injected 20 μ g HSP-HCV, 50 μ gCpG ODN).
3, experimental technique
(1) injection
HSP-HCV and CpGODN are mixed with desired concn with PBS respectively, and HSP-HCV+CpG ODN group is that HSP-HCV and CpGODN are mixed the back injection.Organized injected in mice physiological saline, HSP-HCV, CpG ODN and HSP-HCV+CpG ODN to each respectively in the 1st, 14 and 21 day.In the 24th day inoculation HCV
+B16 cell (1 * 10
5Individual/only), the injection site is that the right side of mice back is subcutaneous.
(2) get tumour and weighing
The weight that mouse is got tumour and takes by weighing tumour is killed in behind inoculated tumour the 15th day.
4, experimental result:
Table 1-2 CpG ODN stimulates mouse CTL to kill and wound the enhancement of HCV infection cytoactive in vivo to HSP65-HCV
| Group | Tumor weight (gram) |
| Physiological saline | 6.23±1.34 |
| HSP-HCV | 3.02±0.63 |
| CpG ODN1 | 5.60±1.33 |
| HSP-HCV+CpG ODN1 | 1.23±0.41 |
| CpG ODN2 | 5.89±0.94 |
| HSP-HCV+CpG ODN2 | 1.32±0.77 |
| CpG ODN3 | 6.33±1.22 |
| HSP-HCV+CpG ODN3 | 0.91±0.54 |
| CpG ODN4 | 5.88±1.18 |
| HSP-HCV+CpG ODN4 | 2.01±0.12 |
| CpGODN5 | 6.17±1.34 |
| HSP-HCV+CpG ODN5 | 1.35±0.34 |
| CpGODN6 | 5.88±1.45 |
| HSP-HCV+CpG ODN6 | 0.77±0.22 |
| CpG ODN7 | 6.05±1.56 |
| HSP-HCV+CpG ODN7 | 1.79±0.36 |
| CpG ODN8 | 5.96±0.98 |
| HSP-HCV+CpG ODN8 | 0.77±0.36 |
| CpG ODN9 | 6.02±1.16 |
| HSP-HCV+CpG ODN9 CpG ODN10 HSP-HCV+CpG ODN10 | 1.23±0.62 5.68±1.17 1.26±0.59 |
5, conclusion
The single chain deoxynucleotide (CpG ODN) that contains CpG can significantly strengthen tubercule bacillus heat shock protein(HSP) 65 multi-epitope HCV cAg fusion roteins stimulates mouse CTL to kill and wound HCV infection cell activity (p＜0.05) in vivo, and its performance is: the energy for growth that the mouse of combined utilization CpG ODN and tubercule bacillus heat shock protein(HSP) 65 multi-epitope HCV cAg fusion roteins suppresses the tumour cell of expression of HCV cAg significantly strengthens.
Embodiment 4 contains the single chain deoxynucleotide of CpG to heat shock protein(HSP) chlamydia trachomatis major outer membrane albumen epitope antigen
Peptide fusion protein induces the active enhancement of specific CTL
1, material:
Tubercule bacillus heat shock protein(HSP) 65 and chlamydia trachomatis major outer membrane proteantigen peptide fusion protein (HSP65-Chla) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (Chla of transfection chlamydia trachomatis major outer membrane proteantigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
40 of the female C57/BL6 mouse in employing 6-8 week, every group 10, be divided into physiological saline group (injecting normal saline), HSP65-Chla organizes (injecting 20 μ g HSP65-Chla), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP65-Chla+CpG ODN organizes (injecting 20 μ g HSP65-Chla, 50 μ g CpG ODN).
3, experimental technique
(1) injection
HSP65-Chla and CpGODN are mixed with desired concn with PBS respectively, and HSP65-Chla+CpG ODN group is that HSP65-Chla and CpGODN are mixed the back injection.Organized injected in mice physiological saline, HSP65-Chla, CpG ODN and HSP65-Chla+CpG ODN to each respectively in the 1st, 14 and 21 day.
(2) preparation effector cell
At the 26th day mouse being taken off neck puts to death.Get mouse boosting cell or lymph-node cell according to a conventional method, below operation is as the relevant statement of embodiment 1.
(3) preparation target cell
Adopt the IMDM culture medium culturing Chla of 10%FBS
+The B16 cell.With
51The Chla of Cr mark
+The B16 cell is done target cell, the relevant statement of following operation such as embodiment 1.
(4) cellulotoxic experiment
Will
51The Chla of Cr mark
+The B16 cell joins in the hole of 96 well culture plates in the IMDM of 10%FBS substratum, the relevant statement of following operation and cytotoxic calculating such as embodiment 1.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 2CpG ODN induces the active enhancement of specific CTL to HSP-Chla
| Group | Specific killing rate (%) |
| Physiological saline | 1.49±0.92 |
| HSP-Chla | 10.13±4.49 |
| CpG ODN1 | 2.53±1.22 |
| HSP-Chla+CpG ODN1 | 16.47±3.91 |
| CpG ODN2 | 0.79±0.62 |
| HSP-Chla+CpG ODN2 | 17.68±5.12 |
| CpG ODN3 | 1.02±0.67 |
| HSP-Chla+CpG ODN3 | 27.28±5.19 |
| CpG ODN4 | 1.80±0.57 |
| HSP-Chla+CpG ODN4 | 25.59±3.95 |
| CpG ODN5 | 0.94±0.87 |
| HSP-Chla+CpG ODN5 | 31.34±6.18 |
| CpG ODN6 | 1.23±1.11 |
| HSP-Chla+CpG ODN6 | 23.27±4.16 |
| CpG ODN7 | 1.51±0.87 |
| HSP-Chla+CpG ODN7 | 28.34±6.31 |
| CpG ODN8 | 0.79±0.45 |
| HSP-Chla+CpG ODN8 | 27.95±5.93 |
| CpG ODN9 | 1.76±1.01 |
| HSP-Chla+CpG ODN9 CpG ODN 10 HSP-Chla+CpG ODN 10 | 30.07±4.99 1.48±0.89 29.98±5.76 |
5, conclusion
The single chain deoxynucleotide that contains CpG can obviously strengthen the activity (p＜0.05) that tubercule bacillus heat shock protein(HSP) 65 and chlamydia trachomatis major outer membrane proteantigen peptide fusion protein induce the chlamydozoan specific CTL.This CTL can kill and wound in vivo and infect chlamydial cell.Therefore, the single chain deoxynucleotide that contains CpG can obviously strengthen the activity of tubercule bacillus heat shock protein(HSP) 65 and the treatment of chlamydia trachomatis major outer membrane proteantigen peptide fusion protein and prevention choamydiae infection and relative disease thereof.
Embodiment 5 contains the single chain deoxynucleotide of CpG to tubercule bacillus heat shock protein(HSP) 65 and human prostate-specific antigen (Prostate specific antigen, PSA) enhancement of epitope antigen peptide fusion protein immunostimulation
One, CpG ODN induces the active enhancement of specific CTL to HSP65-HCV
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and human prostate-specific antigen (Prostate specificantigen, PSA) antigen peptide fusion rotein (HSP-PSA), the single chain deoxynucleotide (CpG ODN) that contains CpG, the B16 cell (PSA of transfection PSA antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
40 of the male C57/BL6 mouse in employing 6-8 week, every group 10, be divided into physiological saline group (injecting normal saline), HSP-PSA organizes (injecting 20 μ g HSP-PSA), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-PSA+CpG ODN organizes (injecting 20 μ g HSP-PSA, 50 μ g CpG ODN).
3, experimental technique
(1) injection
Organized injected in mice physiological saline, HSP-PSA, CpG ODN and HSP-PSA+CpG ODN to each respectively in the 1st, 14 and 21 day.
(2) preparation effector cell
At the 26th day mouse being taken off neck puts to death.Get mouse boosting cell or lymph-node cell according to a conventional method, the preparation single cell suspension.With the IMDM substratum re-suspended cell that contains 10%FBS, mouse Pi cell conditioned medium and HSP-PSA (200 μ g/ml) that the ConA of adding 10% stimulates.37 ℃, 5%CO
2Cultivated 7 days.Harvested cell is the effector cell.
(3) preparation target cell
Employing contains the B16 cell (PSA of the IMDM culture medium culturing transfection PSA antigen peptide gene of 10%FBS
+The B16 cell).With
51Cr mark PSA
+The B16 cell, (cultivated 1 hour, 37 ℃, 5%CO
2).With the IMDM washed cell that contains 10%FBS, totally three times.
(4) cellulotoxic experiment
Will
51Cr mark PSA
+The B16 cell joins in the hole of 96 well culture plates in the IMDM of 10%FBS substratum, and every hole 100 μ l contain 1 * 10
4Individual cell.Imitate target than adding the effector cell by 100: 1, establish three multiple holes.The relevant statement of following operation and cytotoxic calculating such as embodiment 1.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 3-1CpG ODN induces the active enhancement of specific CTL to HSP-PSA
| Group | Specific killing rate (%) |
| Physiological saline | 0.22±0.19 |
| HSP-PSA | 12.39±4.67 |
| CpG ODN1 | 0.27±0.23 |
| HSP-PSA+CpG ODN1 | 21.39±5.45 |
| CpG ODN2 | 0.55±0.37 |
| HSP-PSA+CpG ODN2 | 22.89±4.12 |
| CpG ODN3 | 0.70±0.41 |
| HSP-PSA+CpG ODN3 | 19.85±5.27 |
| CpGODN4 | 0.83±0.65 |
| HSP-PSA+CpG ODN4 | 32.32±5.69 |
| CpG ODN5 | 0.45±0.31 |
| HSP-PSA+CpG ODN5 | 23.00±2.98 |
| CpG ODN6 | 1.04±0.34 |
| HSP-PSA+CpG ODN6 | 31.22±5.12 |
| CpG ODN7 | 1.51±1.22 |
| HSP-PSA+CpG ODN7 | 31.34±6.65 |
| CpG ODN8 | 0.89±0.65 |
| HSP-PSA+CpG ODN8 | 24.57±4.89 |
| CpG ODN9 | 0.74±0.61 |
| HSP-PSA+CpG ODN9 CpG ODN10 HSP-PSA+CpG ODN10 | 27.02±5.51 0.84±0.58 29.02±4.62 |
5, conclusion:
The single chain deoxynucleotide that contains CpG can obviously strengthen the activity (p＜0.05) that tubercule bacillus heat shock protein(HSP) 65 and PSA antigen peptide fusion protein immunization induce the PSA specific CTL, and this CTL can kill and wound the tumour cell of expressing PSA.Therefore, the single chain deoxynucleotide that contains CpG can obviously strengthen the biologic activity of prevention of heat shock protein(HSP) PSA antigen peptide fusion rotein and treatment prostate cancer.
Two, CpG ODN is to the anti-enhancement of expressing the PSA tumor promotion of HSP65-PSA
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and human prostate-specific antigen (Prostate specificantigen, PSA) antigen peptide fusion rotein (HSP-PSA), the single chain deoxynucleotide (CpG ODN) that contains CpG, the B16 cell (PSA of transfection PSA antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
40 of the male C57/BL6 mouse in employing 6-8 week, every group 10, be divided into physiological saline group (injecting normal saline), HSP-PSA organizes (injecting 20 μ g HSP-PSA), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-PSA+CpG ODN organizes (injecting 20 μ g HSP-PSA, 50 μ g CpG ODN).
3, experimental technique
(1) injection
HSP-PSA and CpG ODN prepare with PBS, and HSP-PSA+CpG ODN group is that HSP-PSA and CpG ODN are mixed the back injection.Gave injected in mice physiological saline, HSP-PSA, CpG ODN and HSP-PSA+CpG ODN respectively in the 1st, 14 and 21 day.In the 28th day inoculation PSA
+B16 cell (1 * 10
5/ only), the injection site is that the right back back of mouse is subcutaneous.
(2) get tumour and weighing
The weight that mouse is got tumour and claims tumour is killed in behind inoculated tumour the 15th day.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 3-2CpG ODN is to the anti-enhancement of expressing the PSA tumor promotion of HSP65-PSA
| Group | Tumor weight (gram) |
| Physiological saline | 5.12±1.22 |
| HSP-PSA | 3.33±0.61 |
| CpG ODN1 | 4.60±1.00 |
| HSP-PSA+CpG ODN1 | 1.12±0.33 |
| CpG ODN2 | 5.00±0.99 |
| HSP-PSA+CpG ODN2 | 1.11±0.65 |
| CpG ODN3 | 4.91±1.00 |
| HSP-PSA+CpG ODN3 | 0.98±0.48 |
| CpG ODN4 | 4.88±0.87 |
| HSP-PSA+CpG ODN4 | 1.01±0.34 |
| CpG ODN5 | 5.17±0.73 |
| HSP-PSA+CpG ODN5 | 0.98±0.51 |
| CpG ODN6 | 4.77±0.98 |
| HSP-PSA+CpG ODN6 | 1.30±0.33 |
| CpG ODN7 | 5.05±1.21 |
| HSP-PSA+CpG ODN7 | 1.66±0.41 |
| CpG ODN8 | 4.99±1.01 |
| HSP-PSA+CpG ODN8 | 0.88±0.41 |
| CpG ODN9 | 4.88±1.02 |
| HSP-PSA+CpG ODN9 CpG ODN10 HSP-PSA+CpG ODN 10 | 1.12±0.60 5.38±1.22 1.34±0.58 |
5, conclusion
The single chain deoxynucleotide that contains CpG can obviously strengthen tubercule bacillus heat shock protein(HSP) 65 and suppress to express the growth (p＜0.05) of PSA tumour cell with PSA antigen peptide fusion rotein.The single chain deoxynucleotide that contains CpG can obviously strengthen the biologic activity of heat shock protein(HSP) and prevention of PSA antigen peptide fusion rotein and treatment prostate cancer.
Embodiment 6 contains the enhancement of the single chain deoxynucleotide of CpG to heat shock protein(HSP)-MUC1 antigen peptide fusion protein immunization hormesis
One, CpG ODN induces the active enhancement of specific CTL to HSP65-MUC1
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and MUC1 antigen peptide fusion rotein (HSP-MUC1) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (MUC1 of transfection MUC1 antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
40 of the female C57/BL6 mouse in employing 6-8 week, every group 10, be divided into physiological saline group (injecting normal saline), HSP-MUC1 organizes (injecting 20 μ g HSP-MUC1), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-MUC1+CpG ODN organizes (injecting 20 μ g HSP-MUC1,50 μ g CpG ODN).
3, experimental technique
(1) injection
HSP-MUC1 and CpG ODN prepare to desired concn with PBS, and HSP-MUC1+CpG ODN group is that HSP-MUC1 and CpG ODN are mixed the back injection.Organized injected in mice physiological saline, HSP-MUC1, CpG ODN and HSP-MUC1+CpG ODN to each respectively in the 1st, 14 and 21 day.
(2) preparation effector cell
At the 26th day mouse being taken off neck puts to death.Get mouse boosting cell or lymph-node cell according to a conventional method, the preparation single cell suspension.With the IMDM substratum re-suspended cell that contains 10%FBS, mouse Pi cell conditioned medium and HSP-MUC1 (200 μ g/ml) that the ConA of adding 10% stimulates.37 ℃, 5%CO
2Cultivated 7 days.Harvested cell is the effector cell.
(3) preparation target cell
Adopt the IMDM culture medium culturing MUC1 of 10%FBS
+The B16 cell.With
51Cr mark PSA
+The B16 cell (cultivated 1 hour, 37 ℃, 5%CO
2).With the IMDM washed cell that contains 10%FBS, totally three times.
(4) cellulotoxic experiment
Will
51Cr mark MUC1
+The B16 cell joins in the hole of 96 well culture plates in the IMDM of 10%FBS substratum, and every hole 100 μ l contain 1 * 10
4Individual cell.Imitate target than adding the effector cell by 100: 1, establish three multiple holes.The relevant statement of following operation and cytotoxic calculating such as embodiment 1.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 4-1CpG ODN induces the active enhancement of specific CTL to HSP65-MUC1
| Group | Specific killing rate (%) |
| Physiological saline | 0.46±0.43 |
| HSP-MUC1 | 14.23±3.56 |
| CpG ODN1 | 0.59±0.44 |
| HSP-MUC1+CpG ODN1 | 20.43±4.91 |
| CpG ODN2 | 0.41±0.31 |
| HSP-MUC1+CpG ODN2 | 25.12±5.13 |
| CpGODN3 | 0.65±0.32 |
| HSP-MUC1+CpG ODN3 | 21.23±4.91 |
| CpG ODN4 | 0.77±0.49 |
| HSP-MUC1+CpG ODN4 | 25.01±4.15 |
| CpG ODN5 | 0.51±0.42 |
| HSP-MUC1+CpG ODN5 | 29.12±3.19 |
| CpG ODN6 | 0.74±0.52 |
| HSP-MUC1+CpG ODN6 | 28.82±4.09 |
| CpG ODN7 | 1.01±0.78 |
| HSP-MUC1+CpG ODN7 | 27.65±4.97 |
| CpG ODN8 | 0.76±0.47 |
| HSP-MUC1+CpG ODN8 | 29.11±5.17 |
| CpG ODN9 | 0.65±0.34 |
| HSP-MUC1+CpG ODN9 CpG ODN10 HSP-MUC1+CpG ODN10 | 22.23±4.15 0.85±0.44 26.22±5.13 |
5, conclusion:
The single chain deoxynucleotide that contains CpG can obviously strengthen the activity (p＜0.05) that tubercule bacillus heat shock protein(HSP) 65-MUC1 antigen peptide fusion rotein induces the MUC1 specificity cell toxicity T lymphocyte, and this CTL can kill and wound the tumour cell of expressing MUC1.Therefore, the single chain deoxynucleotide that contains CpG can obviously strengthen the biologic activity that MUC1 tumour such as mammary cancer, ovarian cancer, lung cancer, prostate cancer, colorectal cancer etc. are expressed in the prevention of tubercule bacillus heat shock protein(HSP) 65-MUC1 antigen peptide fusion rotein and treatment.
Two, CpG ODN is to the anti-enhancement of expressing the MUC1 tumor promotion of HSP65-MUC1
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and MUC1 antigen peptide fusion rotein (HSP-MUC1) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (MUC1 of transfection MUC1 antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping: the female C57/BL6 mouse of adopting 6-8 week, be divided into physiological saline group (injecting normal saline), HSP-MUC1 organizes (injecting 20 μ g HSP-MUC1), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-MUC1+CpG ODN group (is injected 20 μ g HSP-MUC1,50 μ g CpG ODN), 10 every group.
3, experimental technique
(1) injection
In the 28th day inoculation MUC1
+B16 cell (1 * 10
5/ only), the injection site is that the right back back of mouse is subcutaneous.
(2) get tumour and weighing
Behind inoculated tumour the 15th day killed mouse and claimed the weight of tumour.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 4-2CpG ODN is to the anti-enhancement of expressing the MUC1 tumor promotion of HSP65-MUC1
| Group | Tumor weight (gram) |
| Physiological saline | 5.68±1.34 |
| HSP-MUC1 | 3.57±0.57 |
| CpG ODN1 | 5.60±1.12 |
| HSP-MUC1+CpG ODN1 | 2.01±0.45 |
| CpG ODN2 | 5.00±0.99 |
| HSP-MUC1+CpG ODN2 | 1.11±0.65 |
| CpG ODN3 | 4.99±1.56 |
| HSP-MUC1+CpG ODN3 | 1.23±0.38 |
| CpG ODN4 | 5.55±0.89 |
| HSP-MUC1+CpG ODN4 | 1.13±0.23 |
| CpG ODN5 | 5.45±1.66 |
| HSP-MUC1+CpG ODN5 | 1.39±0.50 |
| CpG ODN6 | 5.37±1.65 |
| HSP-MUC1+CpG ODN6 | 1.32±0.41 |
| CpG ODN7 | 5.33±1.43 |
| HSP-MUC1+CpG ODN7 | 1.35±0.36 |
| CpG ODN8 | 5.29±0.89 |
| HSP-MUC1+CpG ODN8 | 1.31±0.50 |
| CpG ODN9 | 4.99±1.56 |
| HSP-MUC1+CpG ODN9 CpG ODN10 HSP-MUC1+CpG ODN10 | 1.09±0.55 5.32±1.43 1.12±0.47 |
5, conclusion
The single chain deoxynucleotide that contains CpG can obviously strengthen the growth (p＜0.05) that tubercule bacillus heat shock protein(HSP) 65-MUC1 antigen peptide fusion rotein suppresses to express the MUC1 tumour cell.The single chain deoxynucleotide that contains CpG can obviously strengthen the biologic activity that MUC1 tumour such as mammary cancer, ovarian cancer, lung cancer, prostate cancer, colorectal cancer etc. are expressed in the prevention of tubercule bacillus heat shock protein(HSP) 65-MUC1 antigen peptide fusion rotein and treatment.
Embodiment 7 contains the enhancement of the single chain deoxynucleotide of CpG to heat shock protein(HSP) HER2 antigen peptide fusion protein immunization hormesis
One, CpG ODN induces the active enhancement of specific CTL to HSP65-HER-2
1, material:
Tubercule bacillus heat shock protein(HSP) 65 and HER-2 antigen peptide fusion rotein (HSP-HER-2) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (HER-2 of transfection HER-2 antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
Adopt the female C57/BL6 mouse in 6-8 week, be divided into physiological saline group (injecting normal saline), HSP-HER-2 organizes (injecting 20 μ g HSP-HER-2), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-HER-2+CpG ODN group (is injected 20 μ g HSP-HER-2,50 μ g CpG ODN), 10 every group.
3, experimental technique
(1) injection
HSP-HER-2 and CpG ODN prepare with PBS, and HSP-HER-2+CpG ODN mixes the back injection with HSP-HER-2 and CpG ODN.Gave injected in mice physiological saline, HSP-HER-2, CpG ODN and HSP-HER-2+CpG ODN respectively in the 1st, 14 and 21 day.
(2) preparation effector cell
At the 26th day mouse being taken off neck puts to death.Get mouse boosting cell or lymph-node cell according to a conventional method, the preparation single cell suspension.With the IMDM substratum re-suspended cell that contains 10%FBS, mouse Pi cell conditioned medium and HSP-HER-2 (200 μ g/ml) that the ConA of adding 10% stimulates.37 ℃, 5%CO
2Cultivated 7 days.Harvested cell is the effector cell.
(3) preparation target cell
Adopt the B16 cell (HER-2 of the IMDM culture medium culturing transfection HER-2 antigen peptide gene of 10%FBS
+The B16 cell).With
51Cr mark HER-2
+The B16 cell (cultivated 1 hour, 37 ℃, 5%CO
2).With the IMDM washed cell that contains 10%FBS, totally three times.
(4) cellulotoxic experiment
Will
51Cr mark HER-2
+The B16 cell joins in the hole of 96 well culture plates in the IMDM of 10%FBS substratum, and every hole 100 μ l contain 1 * 10
4Individual cell.Imitate target than adding the effector cell by 100: 1, establish three multiple holes.
The relevant statement of following operation and cytotoxic calculating such as embodiment 1.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 5-1CpG ODN induces the active enhancement of specific CTL to HSP65-HHER-2
| Group | Specific killing rate (%) |
| Physiological saline | 0.39±0.37 |
| HSP-HER-2 | 16.34±3.39 |
| CpG ODN1 | 0.46±0.33 |
| HSP-HER-2+CpG ODN1 | 19.95±3.89 |
| CpG ODN2 | 0.53±0.29 |
| HSP-HER-2+CpG ODN2 | 22.33±4.97 |
| CpGODN3 | 0.71±0.29 |
| HSP-HER-2+CpG ODN3 | 31.19±5.19 |
| CpG ODN4 | 0.63±0.42 |
| HSP-HER-2+CpG ODN4 | 22.23±3.91 |
| CpG ODN5 | 0.45±0.37 |
| HSP-HER-2+CpG ODN5 | 24.54±3.94 |
| CpG ODN6 | 0.57±0.49 |
| HSP-HER-2+CpG ODN6 | 25.79±3.39 |
| CpG ODN7 | 0.98±0.55 |
| HSP-HER-2+CpG ODN7 | 29.22±4.12 |
| CpG ODN8 | 0.66±0.50 |
| HSP-HER-2+CpG ODN8 | 23.32±5.01 |
| CpG ODN9 | 0.61±0.39 |
| HSP-HER-2+CpG ODN9 CpG ODN10 HSP-HER-2+CpG ODN 10 | 24.19±3.92 0.78±0.37 23.87±3.78 |
5, conclusion:
The single chain deoxynucleotide that contains CpG can obviously strengthen the activity (p＜0.05) that tubercule bacillus heat shock protein(HSP) and HER-2 antigen peptide fusion protein immunization induce the HER-2 specificity cell toxicity T lymphocyte, and this CTL can kill and wound the tumour cell of expressing HER-2.Therefore, the single chain deoxynucleotide that contains CpG can obviously strengthen the biologic activity that HER-2 tumour such as mammary cancer and ovarian cancer etc. are expressed in tubercule bacillus heat shock protein(HSP) 65 and prevention of HER-2 antigen peptide fusion rotein and treatment.
Two, CpG ODN is to the anti-enhancement of expressing the HER-2 tumor promotion of HSP65-HER-2
1, material:
Tubercule bacillus heat shock protein(HSP) 65 (HSP65) and HER-2 antigen peptide fusion rotein (HSP-HER-2) contain the single chain deoxynucleotide (CpG ODN) of CpG, the B16 cell (HER-2 of transfection HER-2 antigen peptide gene
+The B16 cell).
2, laboratory animal and grouping:
Adopt the female C57/BL6 mouse in 6-8 week, be divided into physiological saline group (injecting normal saline), HSP-HER-2 organizes (injecting 20 μ g HSP-HER-2), CpG ODN organizes (injecting 50 μ g CpG ODN), HSP-HER-2+CpG ODN group (is injected 20 μ g HSP-HER-2,50 μ g CpG ODN), 10 every group.
3, experimental technique
(1) injection
Gave injected in mice physiological saline, HSP-HER-2, CpG ODN and HSP-HER-2+CpG ODN respectively in the 1st, 14 and 21 day.In the 28th day inoculation HER-2
+B16 cell (1 * 10
5/ only), the injection site is that the right back back of mouse is subcutaneous.
(2) get tumour and weighing
Behind inoculated tumour the 15th day killed mouse and claimed the weight of tumour.
4, experimental result:
The results are shown in following table, the average (n=10) of 10 data represented mouse data wherein.
Table 5-2CpG ODN is to the anti-enhancement of expressing the HER-2 tumor promotion of HSP65-HER-2
| Group | Tumor weight (gram) |
| Physiological saline | 4.96±1.22 |
| HSP-HER2 | 3.22±0.51 |
| CpG ODN1 | 5.00±1.01 |
| HSP-HER2+CpG ODN 1 | 1.47±0.34 |
| CpG ODN2 | 4.87±1.11 |
| HSP-HER2+CpG ODN2 | 0.89±0.54 |
| CpG ODN3 | 4.55±1.03 |
| HSP-HER2+CpG ODN3 | 0.87±0.35 |
| CpG ODN4 | 4.80±0.76 |
| HSP-HER2+CpG ODN4 | 0.56±0.52 |
| CpG ODN5 | 5.04±1.26 |
| HSP-HER2+CpG ODN5 | 1.27±0.49 |
| CpGODN6 | 3.98±1.43 |
| HSP-HER2+CpG ODN6 | 0.79±0.35 |
| CpG ODN7 | 5.13±0.89 |
| HSP-HER2+CpG ODN7 | 1.13±0.22 |
| CpG ODN8 | 4.76±1.16 |
| HSP-HER2+CpG ODN8 | 0.95±0.29 |
| CpG ODN9 | 4.75±1.25 |
| HSP-HER2+CpG ODN9 CpG ODN10 HSP-HER2+CpG ODN10 | 0.79±0.68 5.12±1.34 0.86±0.48 |
5, conclusion:
The single chain deoxynucleotide that contains CpG can obviously strengthen tubercule bacillus heat shock protein(HSP) 65 and suppress to express the growth (p＜0.05) of HER-2 tumour cell with HER-2 antigen peptide fusion rotein.The single chain deoxynucleotide that contains CpG can obviously strengthen tubercule bacillus heat shock protein(HSP) 65 and prevent and treat the biologic activity of expressing HER-2 tumour such as mammary cancer and ovarian cancer etc. with HER-2 antigen peptide fusion rotein.
Sequence table
＜110〉Changchun Huapu Biotechnology Co., Ltd.
＜120〉contain single chain deoxynucleotide and its vaccine composition and the application thereof of CpG
<160>180
<210>1
<211>21
<212>DNA
<213>artificial
<400>1
ggggacgata cgtcgggggg g 21
<210>2
<211>22
<212>DNA
<213>artificial
<400>2
ggggtcgttc gtcgttgggg gg 22
<210>3
<211>20
<212>DNA
<213>artificial
<400>3
ggggataacg ttgcgggggg 20
<210>4
<211>21
<212>DNA
<213>artificial
<400>4
ggggtgcaac gttcaggggg g 21
<210>5
<211>24
<212>DNA
<213>artificial
<400>5
ggggtgctgg ccgtcgttgg gggg 24
<210>6
<211>21
<212>DNA
<213>artificial
<400>6
ggggtcgttg ccgtcggggg g 21
<210>7
<211>21
<212>DNA
<213>artificial
<400>7
ggggacgata tcgatggggg g 21
<210>8
<211>22
<212>DNA
<213>artificial
<400>8
ggggtcctac gtaggagggg gg 22
<210>9
<211>22
<212>DNA
<213>artificial
<400>9
tcgtaacgtt gtttttaacg tt 22
<210>10
<211>21
<212>DNA
<213>artificial
<400>10
tcgtcgtata cgacgatcgt 21
<210>11
<211>20
<212>DNA
<213>artificial
<400>11
tcgtcgtttt gtcgttgggg 20
<210>12
<211>20
<212>DNA
<213>artificial
<400>12
tcgtcgtttg cgttgtcgtt 20
<210>13
<211>20
<212>DNA
<213>artificial
<400>13
tcgtcgcttt gtcgttgggg 20
<210>14
<211>18
<212>DNA
<213>artificial
<400>14
tcctgtcgtt ttgtcgtt 18
<210>15
<211>18
<212>DNA
<213>artificial
<400>15
tcgtcgttgt cgttcgct 18
<210>16
<211>17
<212>DNA
<213>artificial
<400>16
tgtcgttcct tgtcgtt 17
<210>17
<211>25
<212>DNA
<213>artificial
<400>17
tcgtcgttac cgatgacgtc gccgt 25
<210>18
<211>26
<212>DNA
<213>artificial
<400>18
tcgtcgggtg cgacgtcgca gggggg 26
<210>19
<211>27
<212>DNA
<213>artificial
<400>19
tcgtcgggtg cgacgatcgt cgggggg 27
<210>20
<211>29
<212>DNA
<213>artificial
<400>20
tcgtcgtttg catcgatgca gtcgtcgtt 29
<210>21
<211>27
<212>DNA
<213>artificial
<400>21
tcgtcgtttg catcgatgca ggggggg 27
<210>22
<211>24
<212>DNA
<213>artificial
<400>22
accggtatcg atgccggtgg gggg 24
<210>23
<211>27
<212>DNA
<213>artificial
<400>23
ggggtccatg acgttcctga agggggg 27
<210>24
<211>26
<212>DNA
<213>artificial
<400>24
tcgtcgtttt gacgatcgtc gggggg 26
<210>25
<211>30
<212>DNA
<213>artificial
<400>25
ttcgtcgttt gatcgatgtt cgttgggggg 30
<210>26
<211>24
<212>DNA
<213>artificial
<400>26
ttcgtcgttg tgatcgatgg gggg 24
<210>27
<211>28
<212>DNA
<213>artificial
<400>27
tatcgatgtt ttcgtcgtcg ttgggggg 28
<210>28
<211>28
<212>DNA
<213>artificial
<400>28
ttcgttgcat cgatgcatcg ttgggggg 28
<210>29
<211>24
<212>DNA
<213>artificial
<400>29
ttcgcttcgc ttttcgcttc gctt 24
<210>30
<211>20
<212>DNA
<213>artificial
<400>30
tcgcctcgtc gccttcgagc 20
<210>31
<211>19
<212>DNA
<213>artificial
<400>31
tcgtgtgcgt gccgttggg 19
<210>32
<211>20
<212>DNA
<213>artificial
<400>32
tcgtcgaggg cgccggtgac 20
<210>33
<211>20
<212>DNA
<213>artificial
<400>33
tcgtcgccgg tgggggtgtg 20
<210>34
<211>20
<212>DNA
<213>artificial
<400>34
tcgtcgtacg caattgtctt 20
<210>35
<211>20
<212>DNA
<213>artificial
<400>35
tcgcccaccg gtgggggggg 20
<210>36
<211>21
<212>DNA
<213>artificial
<400>36
tcgtcgcaga ccggtctggg g 21
<210>37
<211>20
<212>DNA
<213>artificial
<400>37
gggggacgtc gccggggggg 20
<210>38
<211>20
<212>DNA
<213>artificial
<400>38
ggatccgtac gcatgggggg 20
<210>39
<211>20
<212>DNA
<213>artificial
<400>39
tcgtcgcggc cggcgccccc 20
<210>40
<211>20
<212>DNA
<213>artificial
<400>40
tcgtcgcggc cgcgaggggg 20
<210>41
<211>21
<212>DNA
<213>artificial
<400>41
tcgaggacaa gattctcgtg c 21
<210>42
<211>26
<212>DNA
<213>artificial
<400>42
tcgaggacaa gattctcgtg caggcc 26
<210>43
<211>21
<212>DNA
<213>artificial
<400>43
tcgtgcaggc caacgaggcc g 21
<210>44
<211>26
<212>DNA
<213>artificial
<400>44
accgccaagg agaagccgca ggaggg 26
<210>45
<211>16
<212>DNA
<213>artificial
<400>45
tcgttgccgt cggccc 16
<210>46
<211>19
<212>DNA
<213>artificial
<400>46
tacaacggcg aggaatacc 19
<210>47
<211>30
<212>DNA
<213>artificial
<400>47
tcggcacgcg acgtgctggc cgtcgtttcc 30
<210>48
<211>21
<212>DNA
<213>artificial
<400>48
gtacaacggc gaggaatacc t 21
<210>49
<211>20
<212>DNA
<213>artificial
<400>49
accgtcgttg ccgtcggccc 20
<210>50
<211>14
<212>DNA
<213>artificial
<400>50
tgctggccgt cgtt 14
<210>51
<211>14
<212>DNA
<213>artificial
<400>51
gtcggcacgc gacg 14
<210>52
<211>19
<212>DNA
<213>artificial
<400>52
gtcggcacgc gacgggggg 19
<210>53
<211>20
<212>DNA
<213>artificial
<400>53
gtcggcacgc gacgcccccc 20
<210>54
<211>22
<212>DNA
<213>artificial
<400>54
tcgttgccgt cggccccccc cc 22
<210>55
<211>19
<212>DNA
<213>artificial
<400>55
tcgttgccgt cggcccccc 19
<210>56
<211>18
<212>DNA
<213>artificial
<400>56
tcgttgccgt cggccccc 18
<210>57
<211>17
<212>DNA
<213>artificial
<400>57
tcgttgccgt cggcccc 17
<210>58
<211>20
<212>DNA
<213>artificial
<400>58
tcgttgccgt cggccccccc 20
<210>59
<211>13
<212>DNA
<213>artificial
<400>59
tcgttgccgt cgg 13
<210>60
<211>14
<212>DNA
<213>artificial
<400>60
tcgttgccgt cggg 14
<210>61
<211>15
<212>DNA
<213>artificial
<400>61
tcgttgccgt cgggg 15
<210>62
<211>16
<212>DNA
<213>artificial
<400>62
tcgttgccgt cggggg 16
<210>63
<211>17
<212>DNA
<213>artificial
<400>63
tcgttgccgt cgggggg 17
<210>64
<211>18
<212>DNA
<213>artificial
<400>64
tcgttgccgt cggggggg 18
<210>65
<211>19
<212>DNA
<213>artificial
<400>65
tcgttgccgt cgggggggg 19
<210>66
<211>20
<212>DNA
<213>artificial
<400>66
tcgttgccgt cggggggggg 20
<210>67
<211>19
<212>DNA
<213>artificial
<400>67
tcgaggacaa gattctcgt 19
<210>68
<211>14
<212>DNA
<213>artificial
<400>68
tcccgctgga cgtt 14
<210>69
<211>27
<212>DNA
<213>artificial
<400>69
tcggcacgcg acgtgctggc cgtcgtt 27
<210>70
<211>21
<212>DNA
<213>artificial
<400>70
tcgtcgcgcc gtcacggggg g 21
<210>71
<211>19
<212>DNA
<213>artificial
<400>71
tcgtgtgcgt gccgttggg 19
<210>72
<211>18
<212>DNA
<213>artificial
<400>72
tcgtcgccgt tgggcggg 18
<210>73
<211>21
<212>DNA
<213>artificial
<400>73
tcgtcgacgt cgttgggcgg g 21
<210>74
<211>26
<212>DNA
<213>artificial
<400>74
tcgcagttgt cgtaacgttg ggcggg 26
<210>75
<211>23
<212>DNA
<213>artificial
<400>75
ttaccggtta acgttggccg gcc 23
<210>76
<211>23
<212>DNA
<213>artificial
<400>76
accggttaac gttgtccccg ggg 23
<210>77
<211>16
<212>DNA
<213>artificial
<400>77
tcgtcgttgg tatgtt 16
<210>78
<211>20
<212>DNA
<213>artificial
<400>78
tcgtcgtcgt cgttgtcgtt 20
<210>79
<211>24
<212>DNA
<213>artificial
<400>79
tcgtcgtcgt cgttgtcgtt gggg 24
<210>80
<211>15
<212>DNA
<213>artificial
<400>80
tcgttcgggg tgccg 15
<210>81
<211>18
<212>DNA
<213>artificial
<400>81
tcgttcgggg taacgatt 18
<210>82
<211>17
<212>DNA
<213>artificial
<400>82
tcgttcgggg taacgtt 17
<210>83
<211>17
<212>DNA
<213>artificial
<400>83
tcgttcgggg taccgat 17
<210>84
<211>21
<212>DNA
<213>artificial
<400>84
tcgttcgggg taccgatggg g 21
<210>85
<211>24
<212>DNA
<213>artificial
<400>85
tcgttgcgct cccatgccgg gggg 24
<210>86
<211>20
<212>DNA
<213>artificial
<400>86
tcgtcgtttc gtcgttgggg 20
<210>87
<211>27
<212>DNA
<213>artificial
<400>87
tcgttgtcgt ttcgctgccg gcggggg 27
<210>88
<211>24
<212>DNA
<213>artificial
<400>88
cgttgacgat cgtcccatgg cggg 24
<210>89
<211>16
<212>DNA
<213>artificial
<400>89
tctgcggcct tcgtcg 16
<210>90
<211>22
<212>DNA
<213>artificial
<400>90
tagtaaccgg tccggcgccc cc 22
<210>91
<211>19
<212>DNA
<213>artificial
<400>91
ttgcagcgct gccggtggg 19
<210>92
<211>23
<212>DNA
<213>artificial
<400>92
tcgtacggcc gccgtacggc ggg 23
<210>93
<211>21
<212>DNA
<213>artificial
<400>93
cggcccatcg agggcgacgg c 21
<210>94
<211>23
<212>DNA
<213>artificial
<400>94
tcgcgtcgac tcccctcgag ggg 23
<210>95
<211>24
<212>DNA
<213>artificial
<400>95
tcgtcgtcga ctcgtggtcg gggg 24
<210>96
<211>20
<212>DNA
<213>artificial
<400>96
tcgggcgccc gatcgggggg 20
<210>97
<211>19
<212>DNA
<213>artificial
<400>97
tcgtcggtct ttcgaaatt 19
<210>98
<211>18
<212>DNA
<213>artificial
<400>98
tcgtgacgtc ctcgagtt 18
<210>99
<211>20
<212>DNA
<213>artificial
<400>99
ggacgatcga tcgtgggggg 20
<210>100
<211>24
<212>DNA
<213>artificial
<400>100
gggatgcatc gatgcatcgg gggg 24
<210>101
<211>20
<212>DNA
<213>artificial
<400>101
gggggaatcg attcgggggg 20
<210>102
<211>20
<212>DNA
<213>artificial
<400>102
ggtgcgacgt cgcagggggg 20
<210>103
<211>26
<212>DNA
<213>artificial
<400>103
tcgtcgggtg catcgatgca gggggg 26
<210>104
<211>24
<212>DNA
<213>artificial
<400>104
ggtgcatcgt acgatgcagg gggg 24
<210>105
<211>18
<212>DNA
<213>artificial
<400>105
gggacgtacg tcgggggg 18
<210>106
<211>21
<212>DNA
<213>artificial
<400>106
tcggggacga tcgtcggggg g 21
<210>107
<211>24
<212>DNA
<213>artificial
<400>107
gggggatcga tatcgatcgg gggg 24
<210>108
<211>24
<212>DNA
<213>artificial
<400>108
gggggatcga cgtcgatcgg gggg 24
<210>109
<211>24
<212>DNA
<213>artificial
<400>109
ggtgcatcga tcgatgcagg gggg 24
<210>110
<211>22
<212>DNA
<213>artificial
<400>110
ggatcgatcg atcgatgggg gg 22
<210>111
<211>22
<212>DNA
<213>artificial
<400>111
ggcgatcgat cgatcggggg gg 22
<210>112
<211>22
<212>DNA
<213>artificial
<400>112
ggggtcgatc gatcgagggg gg 22
<210>113
<211>22
<212>DNA
<213>artificial
<400>113
ggtgcgatcg atcgcagggg gg 22
<210>114
<211>20
<212>DNA
<213>artificial
<400>114
ggtcgcgatc gcgagggggg 20
<210>115
<211>20
<212>DNA
<213>artificial
<400>115
tcgtctttcg actcgttctc 20
<210>116
<211>18
<212>DNA
<213>artificial
<400>116
tcgtcgtttt gcgttctc 18
<210>117
<211>20
<212>DNA
<213>artificial
<400>117
tcatcgactc tcgagcgttc 20
<210>118
<211>21
<212>DNA
<213>artificial
<400>118
atcgtcgact ctcgtgttct c 21
<210>119
<211>20
<212>DNA
<213>artificial
<400>119
tcgactttcg tcgttctgtt 20
<210>120
<211>19
<212>DNA
<213>artificial
<400>120
tcgtcgtttc gtcgttctc 19
<210>121
<211>20
<212>DNA
<213>artificial
<400>121
tcgtcgtcgt cgttgtcgtt 20
<210>122
<211>19
<212>DNA
<213>artificial
<400>122
tcgttctcga ctcgttctc 19
<210>123
<211>23
<212>DNA
<213>artificial
<400>123
tcgacgttcg tcgttcgtcg ttc 23
<210>124
<211>21
<212>DNA
<213>artificial
<400>124
tcgtcgacgt cgttcgttct c 21
<210>125
<211>26
<212>DNA
<213>artificial
<400>125
tgcttgggtg gcagctgcca gggggg 26
<210>126
<211>20
<212>DNA
<213>artificial
<400>126
tgctgctttg ctgcttgggg 20
<210>127
<211>23
<212>DNA
<213>artificial
<400>127
tgcagcttgc tgcttgctgc ttc 23
<210>128
<211>20
<212>DNA
<213>artificial
<400>128
ggggtcaacg ttgagggggg 20
<210>129
<211>26
<212>DNA
<213>artificial
<400>129
tcgtcgggtg caacgttgca gggggg 26
<210>130
<211>26
<212>DNA
<213>artificial
<400>130
tcgtcgggtg cgtcgacgca gggggg 26
<210>131
<211>24
<212>DNA
<213>artificial
<400>131
tcgtcgggtg cgatcgcagg gggg 24
<210>132
<211>30
<212>DNA
<213>artificial
<400>132
tcgtcgggtg cgacgatcgt cgcagggggg 30
<210>133
<211>24
<212>DNA
<213>artificial
<400>133
tcgtcgtgcg acgtcgcagg gggg 24
<210>134
<211>23
<212>DNA
<213>artificial
<400>134
tcgtcgcaga acgttctggg ggg 23
<210>135
<211>21
<212>DNA
<213>artificial
<400>135
tcgtgcgacg tcgcaggggg g 21
<210>136
<211>20
<212>DNA
<213>artificial
<400>136
ggtgcgacgt cgcagatgat 20
<210>137
<211>20
<212>DNA
<213>artificial
<400>137
ggtcgaacgt tcgagatgat 20
<210>138
<211>21
<212>DNA
<213>artificial
<400>138
tcgtgcgacg tcgcagatga t 21
<210>139
<211>25
<212>DNA
<213>artificial
<400>139
tcgtgcgacg atcgtcgcag ggggg 25
<210>140
<211>25
<212>DNA
<213>artificial
<400>140
tcgtatgcat cgatgcatag ggagg 25
<210>141
<211>21
<212>DNA
<213>artificial
<400>141
tcgtcgagcg ctcgatcgga t 21
<210>142
<211>28
<212>DNA
<213>artificial
<400>142
tcgtcgtttc gtagtcgttg acgtcggg 28
<210>143
<211>26
<212>DNA
<213>artificial
<400>143
gggggcgtcg ttttcgtcga cgaatt 26
<210>144
<211>24
<212>DNA
<213>artificial
<400>144
tcgtcggacg ttttccgacg ttct 24
<210>145
<211>24
<212>DNA
<213>artificial
<400>145
actcgagacg cccgttgata gctt 24
<210>146
<211>24
<212>DNA
<213>artificial
<400>146
aacgttggcg tcgacgtcag cgcc 24
<210>147
<211>18
<212>DNA
<213>artificial
<400>147
gacgtcgacg ttgacgct 18
<210>148
<211>18
<212>DNA
<213>artificial
<400>148
ggcgttaacg ttagcgct 18
<210>149
<211>18
<212>DNA
<213>artificial
<400>149
agcgctagcg ctgacgtt 18
<210>150
<211>17
<212>DNA
<213>artificial
<400>15
ctagacgttc aagcgtt 17
<210>151
<211>26
<212>DNA
<213>artificial
<400>151
tcgtcgtttt cgtcgttttc gtcgtt 26
<210>152
<211>22
<212>DNA
<213>artificial
<400>152
tcgtcgtttg tcgtgtgtcg tt 22
<210>153
<211>30
<212>DNA
<213>artificial
<400>153
tcgtcgttgg tcggggtcgt tggggtcgtt 30
<210>154
<211>20
<212>DNA
<213>artificial
<400>154
tcgtcgtttc gtctctcgtt 20
<210>155
<211>21
<212>DNA
<213>artificial
<400>15
tcgtcgtttt gctgcgtcgt t 21
<210>156
<211>20
<212>DNA
<213>artificial
<400>156
gacgatcgtc gacgatcgtc 20
<210>157
<211>21
<212>DNA
<213>artificial
<400>157
tcgtgcatcg atgcaggggg g 21
<210>158
<211>18
<212>DNA
<213>artificial
<400>158
tcgaaacgtt tcgggggg 18
<210>159
<211>19
<212>DNA
<213>artificial
<400>159
tcggacgatc gtcgggggg 19
<210>160
<211>20
<212>DNA
<213>artificial
<400>160
ggtgcgacgt cgcagggggg 20
<210>161
<211>24
<212>DNA
<213>artificial
<400>161
gtcgttcgta gtcgactacg agtt 24
<210>162
<211>26
<212>DNA
<213>artificial
<400>162
aaaagacgtc gacgtcgact tctttt 26
<210>163
<211>24
<212>DNA
<213>artificial
<400>163
aacgttcgac gtcgaacggg gggg 24
<210>164
<211>28
<212>DNA
<213>artificial
<400>164
gtcgttttcg tcgacgaatt gggggggg 28
<210>165
<211>26
<212>DNA
<213>artificial
<400>165
gtcgttatcg ttttttcgta gggggg 26
<210>166
<211>18
<212>DNA
<213>artificial
<400>166
ggcgttaacg acgggggg 18
<210>167
<211>17
<212>DNA
<213>artificial
<400>167
aacgacgacg ttggggg 17
<210>168
<211>19
<212>DNA
<213>artificial
<400>168
agacgtctaa cgtcggggg 19
<210>169
<211>23
<212>DNA
<213>artificial
<400>169
gtctattttg tacgtacgtg ggg 23
<210>170
<211>24
<212>DNA
<213>artificial
<400>170
gacgtcgacg tcgacgtcag gggg 24
<210>171
<211>22
<212>DNA
<213>artificial
<400>171
gggggggtcg atcgatgggg gg 22
<210>172
<211>22
<212>DNA
<213>artificial
<400>172
ggggtcgtcg aacgttgggg gg 22
<210>173
<211>25
<212>DNA
<213>artificial
<400>173
ggggtcgatc gttgctagcg ggggg 25
<210>174
<211>25
<212>DNA
<213>artificial
<400>174
gggggacgtt atcgtattgg ggggg 25
<210>175
<211>32
<212>DNA
<213>artificial
<400>175
ggggtcgtcg tttgtcgtgt gtcgttgggg gg 32
<210>176
<211>25
<212>DNA
<213>artificial
<400>176
tgcgacgatc gtcgcacgat cggat 25
<210>177
<211>18
<212>DNA
<213>artificial
<400>177
tgcgacgtcg cacagcgt 18
<210>178
<211>21
<212>DNA
<213>artificial
<400>178
tcgagcgttt tcgctcgaat t 21
<210>179
<211>22
<212>DNA
<213>artificial
<400>179
tcgagcgatc gctcgagggg gg 22
<210>180
<211>20
<212>DNA
<213>artificial
<400>180
acgatcgatc gatcgggggg 20
Claims (36)
1, a kind of can enhancement antigen or the single chain deoxynucleotide that contains CpG of antigen composition immunostimulation, it is characterized in that described single chain deoxynucleotide comprises the sequence that is selected from following formula at least:
(1) (G)
n(L)
nX
1X
2CGY
1Y
2(M)
n(G)
n, X wherein
1Be A, T or G; X
2Be A or T; Y
1Be A or T; Y
2Be A, T or C; L and M are respectively A, T, C or G; N is the integer of 0-6;
(2) (G)
n(L)
nCG (XY)
nCG (M)
n(G)
n, wherein X is A or T; Y is A or T; L and M are respectively A, T, C or G; N is the integer of 0-6;
(3) (TCG)
n(L)
nCG (M)
n(G)
n, wherein L and M are respectively A, T, C or G; N is the integer of 0-6;
(4) (TCG)
n(L)
nX
1X
2CG (M)
n, X wherein
1Be A, T or G; X
2Be A or T; L and M are respectively A, T, C or G; N is the integer of 0-6;
(5) comprise the sequence of TTCGTCG.
2, single chain deoxynucleotide according to claim 1, described single chain deoxynucleotide are selected from the sequence of SEQ ID NO:1-185 shown in arbitrary.
3, single chain deoxynucleotide according to claim 1 and 2, described single chain deoxynucleotide also is included in the modification of each group on its base.
4, single chain deoxynucleotide according to claim 3, described modification comprise that non-thio-modification, thio-modification, part thio-modification, rare base modification, the modification that methylates, sulfydryl, Aminolinker C6 or Thiol-C6S-S are used for and the applied modification mode of other material couplings.
5, according to arbitrary described single chain deoxynucleotide in the claim 1 to 4, described antigen or antigen composition are that heat shock protein(HSP) and antigen peptide merge formed fusion rotein.
6, single chain deoxynucleotide according to claim 5, described heat shock protein(HSP) are tubercule bacillus heat shock protein(HSP) 65.
7, single chain deoxynucleotide according to claim 5, described antigen peptide are selected from multi-epitope core antigen of C type hepatitis virus peptide, chlamydia trachomatis major outer membrane albumen epitope antigen peptide, human prostate-specific antigen peptide, MUC1 antigen peptide or HER-2 antigen peptide.
8, a kind of vaccine composition comprises the arbitrary described single chain deoxynucleotide of claim 1 to 4 and antigen or antigen composition.
9, vaccine composition according to claim 8, described antigen or antigen composition are that heat shock protein(HSP) and antigen peptide merge formed fusion rotein.
10, vaccine composition according to claim 9, described heat shock protein(HSP) are tubercule bacillus heat shock protein(HSP) 65.
11, vaccine composition according to claim 9, described antigen peptide are multi-epitope core antigen of C type hepatitis virus peptide.
12, vaccine composition according to claim 9, described antigen peptide are chlamydia trachomatis major outer membrane albumen epitope antigen peptide.
13, vaccine composition according to claim 9, described antigen peptide behaviour prostate specific antigen peptide.
14, vaccine composition according to claim 9, described antigen peptide are the MUC1 antigen peptide.
15, vaccine composition according to claim 9, described antigen peptide are the HER-2 antigen peptide.
16, the method for the described vaccine composition of a kind of production claim 8 comprises the arbitrary described single chain deoxynucleotide of claim 1 to 4 is mixed with antigen or antigen composition.
17, method according to claim 16, described antigen or antigen composition are that heat shock protein(HSP) and antigen peptide merge formed fusion rotein.
18, method according to claim 17, described heat shock protein(HSP) are tubercule bacillus heat shock protein(HSP) 65.
19, method according to claim 17, described antigen peptide are multi-epitope core antigen of C type hepatitis virus peptide.
20, method according to claim 17, described antigen peptide are chlamydia trachomatis major outer membrane albumen epitope antigen peptide.
21, method according to claim 17, described antigen peptide behaviour prostate specific antigen peptide.
22, method according to claim 17, described antigen peptide are the MUC1 antigen peptide.
23, generation method according to claim 17, described antigen peptide are the HER-2 antigen peptide.
24, the method for a kind of enhancement antigen or antigen composition immunostimulation comprises the arbitrary described single chain deoxynucleotide of claim 1 to 4 and antigen or antigen composition combined utilization.
25, method according to claim 24, described antigen or antigen composition are that heat shock protein(HSP) and antigen peptide merge formed fusion rotein.
26, method according to claim 25, described heat shock protein(HSP) are tubercule bacillus heat shock protein(HSP) 65.
27, method according to claim 25, described antigen peptide are multi-epitope core antigen of C type hepatitis virus peptide.
28, method according to claim 25, described antigen peptide are chlamydia trachomatis major outer membrane albumen epitope antigen peptide.
29, method according to claim 25, described antigen peptide behaviour prostate specific antigen peptide.
30, method according to claim 25, described antigen peptide are the MUC1 antigen peptide.
31, method according to claim 25, described antigen peptide are the HER-2 antigen peptide.
32, arbitrary described vaccine composition is used for the treatment of application in the vaccine of virus infection, infectation of bacteria, parasitic infection, transformation reactions or cancer in preparation in the claim 8 to 15.
33, according to the application of claim 32, the application of described vaccine composition is the mankind or mammal.
34, according to the application of claim 32, described virus infection is infection with hepatitis C virus or the relative disease that caused by this virus infection.
35, according to the application of claim 32, described infectation of bacteria is choamydiae infection or the relative disease that caused by choamydiae infection.
36, according to the application of claim 32, described cancer is prostate cancer, mammary cancer, ovarian cancer, lung cancer, cancer of the stomach, carcinoma of endometrium, salivary-gland carcinoma, gland cancer, colon and the rectum cancer, nonsmall-cell lung cancer or adenocarcinoma of lung.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100029570A CN1810970B (en) | 2005-01-27 | 2005-01-27 | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
| PCT/CN2006/000183 WO2006079291A1 (en) | 2005-01-27 | 2006-01-27 | Artificial synthetic single strand deoxynucleotide and vaccine composition thereof and the use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100029570A CN1810970B (en) | 2005-01-27 | 2005-01-27 | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1810970A true CN1810970A (en) | 2006-08-02 |
| CN1810970B CN1810970B (en) | 2011-05-18 |
Family
ID=36740051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100029570A Active CN1810970B (en) | 2005-01-27 | 2005-01-27 | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1810970B (en) |
| WO (1) | WO2006079291A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007012285A1 (en) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Viral infection resistent single strand deoxynucleosides |
| CN101333237B (en) * | 2007-06-26 | 2012-07-04 | 长春华普生物技术有限公司 | Oligonucleotide with breast carcinoma treating function |
| CN103547674A (en) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | Immunostimulatory oligodeoxynucleotides |
| CN103547675A (en) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | Immunostimulatory oligodeoxynucleotides |
| CN109234280A (en) * | 2018-11-02 | 2019-01-18 | 吉林农业大学 | A kind of sika deer specific C pG oligodeoxynucleotide and its application |
| CN114796476A (en) * | 2021-09-24 | 2022-07-29 | 中国医学科学院医学生物学研究所 | Novel nucleic acid adjuvant system of subunit vaccine and application thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1663316A2 (en) * | 2003-09-25 | 2006-06-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid lipophilic conjugates |
| EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| AR097029A1 (en) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE |
| CN117157320A (en) * | 2021-01-29 | 2023-12-01 | 国家健康科学研究所 | Chlamydia trachomatis antigenic polypeptides and their use for vaccine purposes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400099C (en) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | Recombinant protein vaccine for preventing and treating human prostata cancer |
| US20030072762A1 (en) * | 2001-08-03 | 2003-04-17 | Van De Winkel Jan G. J. | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies |
| CN1268392C (en) * | 2002-05-30 | 2006-08-09 | 北京迪威华宇生物技术有限公司 | Vaccine of recombined albumen for preventing and treating infection of human C type hepatitis virus and its usage |
| CN1243568C (en) * | 2002-08-29 | 2006-03-01 | 北京迪威华宇生物技术有限公司 | Recombination protein for preventing human trachoma bedsnia infestation and its use |
| CN100439386C (en) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | Deoxyoligonucleotide containing CpG single strand for strengthening immunological effect of Protein vaccine |
| JP2004315433A (en) * | 2003-04-16 | 2004-11-11 | Woong-Shick Ahn | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PAPILLOMA VIRUS-INDUCED DISEASE CONTAINING ANTIGENIC PROTEIN OF PAPILLOMA VIRUS AND CpG-OLIGODEOXYNUCLEOTIDE |
-
2005
- 2005-01-27 CN CN2005100029570A patent/CN1810970B/en active Active
-
2006
- 2006-01-27 WO PCT/CN2006/000183 patent/WO2006079291A1/en not_active Application Discontinuation
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007012285A1 (en) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Viral infection resistent single strand deoxynucleosides |
| CN101333237B (en) * | 2007-06-26 | 2012-07-04 | 长春华普生物技术有限公司 | Oligonucleotide with breast carcinoma treating function |
| CN103547674A (en) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | Immunostimulatory oligodeoxynucleotides |
| CN103547675A (en) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | Immunostimulatory oligodeoxynucleotides |
| US9359602B2 (en) | 2011-05-26 | 2016-06-07 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
| CN109234280A (en) * | 2018-11-02 | 2019-01-18 | 吉林农业大学 | A kind of sika deer specific C pG oligodeoxynucleotide and its application |
| CN109234280B (en) * | 2018-11-02 | 2021-08-24 | 吉林农业大学 | Sika deer specific CpG oligodeoxynucleotide and application thereof |
| CN114796476A (en) * | 2021-09-24 | 2022-07-29 | 中国医学科学院医学生物学研究所 | Novel nucleic acid adjuvant system of subunit vaccine and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006079291A1 (en) | 2006-08-03 |
| CN1810970B (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1810970A (en) | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application | |
| CN1248736C (en) | Vaccine composition | |
| CN1240717C (en) | Low-toxicity human interferon-alpha analog | |
| CN1122613A (en) | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable | |
| CN1845995A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| CN1703229A (en) | Compositions and methods for treatment of prostate and other cancers | |
| CN1929860A (en) | Site-specific chemical modification of HIV gp41-derived peptides | |
| CN1865275A (en) | Artificially synthesized single-stranded deoxynucleotide having therapeutic effect on human B cell tumor | |
| CN1771054A (en) | Improved vaccines | |
| CN1313491C (en) | Cat omega interferon and its coding gene and uses | |
| CN1741818A (en) | Nematode polypeptide adjuvant | |
| CN1526718A (en) | Antivira and antitumor deoxyoligonucleotide containing CpG single strand | |
| CN1812797A (en) | Use of double-stranded ribonucleic acid for inducing cell lysis | |
| CN1526719A (en) | Deoxyoligonucleotide containing CpG single strand for strengthening immunological effect of Protein vaccine | |
| CN1182453A (en) | MPL Ligand analogs | |
| CN1256347C (en) | Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof | |
| CN1283793C (en) | Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function | |
| CN1629194A (en) | Super antigen fusion protein for cancer therapy and its producing method | |
| CN1809583A (en) | Antisense oligonucleotides that inhibit expression of hif-1 | |
| CN1268392C (en) | Vaccine of recombined albumen for preventing and treating infection of human C type hepatitis virus and its usage | |
| CN1827640A (en) | Polypeptide for inhibition of angiogenesis and method for preparing same and use thereof | |
| CN1781930A (en) | Deoxy nucleotide containing CpG single chain as adjuvant of hepatitis B virus vaccine | |
| CN1864746A (en) | Gene engineered poly-valence subunit vaccine of Hp AhpC and preparation method thereof | |
| CN1954882A (en) | Use of long active human recombination solubility tumor necrosin alpha receptor in preparation of medicine for treating hepatic failure | |
| CN1284854C (en) | Mosaic type DNA vaccine in use for preventing tuberculosis and immunological therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: High tech Zone of Jilin province Changchun Chaoqun street 130103 No. 191 incubator building block A room 306 Patentee after: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. Address before: 100101 Xinmin Street, Beijing, 4-28/1102-54 Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Shao Yan Document name: Deemed not to have been notified |
|
| DD01 | Delivery of document by public notice | ||
| CP03 | Change of name, title or address |
Address after: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee after: Huapu Biotechnology (Jiangsu) Co.,Ltd. Address before: 130103 Room 306, Block A, Incubation Building, 191 Chaoqun Street, Changchun High-tech Zone, Jilin Province Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 051430 7-9/F, Building A2, No. 769, Taihang South Street, Shijiazhuang Hi tech Industrial Development Zone, Hebei Province Patentee after: Huapu Biotechnology (Hebei) Co.,Ltd. Address before: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee before: Huapu Biotechnology (Jiangsu) Co.,Ltd. |
|
| CP03 | Change of name, title or address |